

PALL CORP  
Form 10-Q  
March 28, 2008



## Table of Contents

|   | <b>Page<br/>No.</b> |
|---|---------------------|
| <b><u>PART I. FINANCIAL INFORMATION</u></b>   |                     |
| <b><u>Item 1. Financial Statements (Unaudited)</u></b>  |                     |
| <u>Condensed Consolidated Balance Sheets as of January 31, 2008 and July 31, 2007</u>   | 3                   |
| <u>Condensed Consolidated Statements of Earnings for the three and six months ended January 31, 2008 and January 31, 2007</u> | 4                   |
| <u>Condensed Consolidated Statements of Cash Flows for the six months ended January 31, 2008 and January 31, 2007</u>         | 5                   |
| <u>Notes to Condensed Consolidated Financial Statements</u>   | 6                   |
| <b><u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>                   | 22                  |
| <b><u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u></b>  | 35                  |
| <b><u>Item 4. Controls and Procedures</u></b>   | 35                  |
| <b><u>PART II. OTHER INFORMATION</u></b>  |                     |
| <b><u>Item 1. Legal Proceedings</u></b>   | 36                  |
| <b><u>Item 1A. Risk Factors</u></b>   | 37                  |
| <b><u>Item 2. Unregistered Sales of Equity Securities and use of Proceeds</u></b>   | 37                  |
| <b><u>Item 6. Exhibits</u></b>  | 37                  |
| <b><u>SIGNATURES</u></b>  |                     |
| <u>EX-31.1: CERTIFICATION</u>   | 38                  |
| <u>EX-31.2: CERTIFICATION</u>   |                     |
| <u>EX-32.1: CERTIFICATION</u>   |                     |
| <u>EX-32.2: CERTIFICATION</u>   |                     |

### Special Note

Along with this report, Pall Corporation (the "Company") is filing its delayed fiscal year 2007 annual report on Form 10-K (2007 Form 10-K) as well as its delayed quarterly report for the first quarter of fiscal year 2008 on Form 10-Q. These reports were delayed pending the completion of an inquiry conducted by the Company's audit committee into the Company's understatement of its United States (U.S.) federal income tax payments and its provision for income taxes. The audit committee completed its inquiry in January 2008. On August 1, 2007, the audit committee, on the recommendation of management, concluded that the Company's previously issued financial statements for each of the eight fiscal years in the period ended July 31, 2006 (including the interim periods within those years), and for each of the fiscal quarters ended October 31, 2006, January 31, 2007 and April 30, 2007, should no longer be relied upon. Accordingly, the Company has restated its previously issued financial statements for those periods in its 2007 Form 10-K. The Company has not amended its previously filed Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q for the periods affected by this restatement.

Edgar Filing: PALL CORP - Form 10-Q

The adjustments made as a result of the restatement are discussed in Note 2, Audit Committee Inquiry and Restatement, to the accompanying condensed consolidated financial statements included in Part I Item 1 Financial Statements (Unaudited). For additional discussion of the inquiry and the restatement adjustments, see Part I Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations Audit Committee Inquiry and Restatement and Note 2 to the accompanying condensed consolidated financial statements. For a description of the material weakness identified by management in internal control over financial reporting with respect to the Company's accounting for income taxes and management's remediation of the material weakness, see Part I Item 4 Controls and Procedures of this Form 10-Q.

**Table of Contents****PART I. FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS.**

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In thousands, except per share data)  
(Unaudited)

| <b>ASSETS</b>                                    | <b>Jan. 31, 2008</b> | <b>July 31, 2007</b> |
|--|----------------------|----------------------|
| Current assets:                                  |                      |                      |
| Cash and cash equivalents                        | \$ 410,265           | \$ 443,036           |
| Accounts receivable                              | 576,204              | 551,393              |
| Inventories                                      | 506,365              | 471,467              |
| Prepaid expenses                                 | 47,142               | 34,135               |
| Other current assets                             | 86,801               | 106,346              |
| Total current assets                             | 1,626,777            | 1,606,377            |
| Property, plant and equipment, net               | 628,071              | 607,900              |
| Goodwill   | 263,653              | 260,205              |
| Intangible assets                                | 48,750               | 47,933               |
| Other non-current assets                         | 311,445              | 186,431              |
| Total assets                                     | \$ 2,878,696         | \$ 2,708,846         |
|  |                      |                      |
| <b>LIABILITIES AND STOCKHOLDERS EQUITY</b>       |                      |                      |
| Current liabilities:                             |                      |                      |
| Notes payable                                    | \$ 63,231            | \$ 39,949            |
| Accounts payable and other current liabilities   | 481,855              | 499,075              |
| Income taxes payable                             | 39,251               | 291,395              |
| Current portion of long-term debt                | 1,783                | 1,771                |
| Total current liabilities                        | 586,120              | 832,190              |
| Long-term debt, net of current portion           | 692,430              | 591,591              |
| Income taxes payable non-current                 | 220,221              |                      |
| Deferred taxes and other non-current liabilities | 229,835              | 224,464              |
| Total liabilities                                | 1,728,606            | 1,648,245            |
| Stockholders equity:                             |                      |                      |
| Common stock, par value \$.10 per share          | 12,796               | 12,796               |
| Capital in excess of par value                   | 168,540              | 159,620              |
| Retained earnings                                | 1,019,471            | 974,945              |
| Treasury stock, at cost                          | (154,850)            | (164,454)            |
| Stock option loans                               | (462)                | (679)                |
| Accumulated other comprehensive income (loss):   |                      |                      |
| Foreign currency translation                     | 168,406              | 142,691              |
| Minimum pension liability                        | (67,036)             | (67,036)             |

Edgar Filing: PALL CORP - Form 10-Q

|  |              |              |
|--|--------------|--------------|
| Unrealized investment gains                | 3,891        | 2,801        |
| Unrealized losses on derivatives           | (666)        | (83)         |
|  | 104,595      | 78,373       |
| Total stockholders' equity                 | 1,150,090    | 1,060,601    |
| Total liabilities and stockholders' equity | \$ 2,878,696 | \$ 2,708,846 |

See accompanying notes to condensed consolidated financial statements.

3

---

Table of Contents

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS**  
(In thousands, except per share data)  
(Unaudited)

|  | Three Months Ended |                                      | Six Months Ended |                                      |
|--|--------------------|--------------------------------------|------------------|--------------------------------------|
|  | Jan. 31,<br>2008   | Jan. 31,<br>2007<br>(As<br>Restated) | Jan. 31,<br>2008 | Jan. 31,<br>2007<br>(As<br>Restated) |
| Net sales                                    | \$ 625,747         | \$ 544,930                           | \$ 1,186,754     | \$ 1,044,218                         |
| Cost of sales                                | 337,471            | 288,460                              | 637,162          | 564,076                              |
| Gross profit                                 | 288,276            | 256,470                              | 549,592          | 480,142                              |
| Selling, general and administrative expenses | 178,845            | 168,203                              | 349,832          | 325,578                              |
| Research and development                     | 18,092             | 15,277                               | 34,987           | 29,511                               |
| Restructuring and other charges/(gains), net | 13,859             | (3,648)                              | 22,628           | 13,440                               |
| Interest expense, net                        | 8,063              | 9,759                                | 15,784           | 20,455                               |
| Earnings before income taxes                 | 69,417             | 66,879                               | 126,361          | 91,158                               |
| Provision for income taxes                   | 21,429             | 22,532                               | 42,271           | 30,810                               |
| Net earnings                                 | \$ 47,988          | \$ 44,347                            | \$ 84,090        | \$ 60,348                            |
| Earnings per share:                          |                    |                                      |                  |                                      |
| Basic  | \$ 0.39            | \$ 0.36                              | \$ 0.68          | \$ 0.49                              |
| Diluted                                      | \$ 0.39            | \$ 0.36                              | \$ 0.68          | \$ 0.49                              |
| Dividends declared per share                 | \$ 0.12            | \$ 0.12                              | \$ 0.36          | \$ 0.23                              |
| Average shares outstanding:                  |                    |                                      |                  |                                      |
| Basic  | 123,372            | 123,185                              | 123,256          | 122,988                              |
| Diluted                                      | 124,572            | 124,504                              | 124,449          | 124,392                              |

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands)  
(Unaudited)

|  | <b>Six Months Ended</b>  |                      |
|--|--------------------------|----------------------|
|  | <b>Jan. 31,<br/>2008</b> | <b>Jan. 31, 2007</b> |
| <b>Operating activities:</b>   |                          |                      |
| Net cash (used)/provided by operating activities                       | \$ (74,905)              | \$ 148,875           |
| <b>Investing activities:</b>   |                          |                      |
| Capital expenditures   | (52,681)                 | (32,210)             |
| Proceeds from sale of retirement benefit assets                        | 11,666                   | 14,864               |
| Purchases of retirement benefit assets                                 | (13,714)                 | (14,018)             |
| Disposals of long lived assets   | 4,605                    | 43,968               |
| Acquisitions of businesses, net of disposals and cash acquired         |                          | (406)                |
| Other  | (2,741)                  | (2,252)              |
| Net cash (used)/provided by investing activities                       | (52,865)                 | 9,946                |
| <b>Financing activities:</b>   |                          |                      |
| Notes payable  | 21,538                   | (8,080)              |
| Dividends paid   | (29,425)                 | (26,885)             |
| Net proceeds from stock plans  | 7,462                    | 24,840               |
| Purchase of treasury stock   |                          | (11,800)             |
| Long-term borrowings   | 119,424                  | 618                  |
| Repayments of long-term debt   | (39,509)                 | (113,819)            |
| Excess tax benefits from stock-based compensation arrangements         | 760                      | 2,919                |
| Net cash provided/(used) by financing activities                       | 80,250                   | (132,207)            |
| Cash flow for period   | (47,520)                 | 26,614               |
| Cash and cash equivalents at beginning of year                         | 443,036                  | 317,657              |
| Effect of exchange rate changes on cash and cash equivalents           | 14,749                   | 1,415                |
| Cash and cash equivalents at end of period                             | \$ 410,265               | \$ 345,686           |
| <b>Supplemental disclosures:</b>                                       |                          |                      |
| Interest paid  | \$ 24,342                | \$ 18,242            |
| Income taxes paid (net of refunds)                                     | 187,232                  | 13,064               |
| See accompanying notes to condensed consolidated financial statements. |                          |                      |



**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(In thousands, except per share data)**  
**(Unaudited)**

**NOTE 1 BASIS OF PRESENTATION**

The condensed consolidated financial information included herein is unaudited. Such information reflects all adjustments of a normal recurring nature, which are, in the opinion of Company management, necessary to present fairly the Company's consolidated financial position, results of operations and cash flows as of the dates and for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes set forth in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2007 (2007 Form 10-K).

**NOTE 2 AUDIT COMMITTEE INQUIRY AND RESTATEMENT**

As discussed in the 2007 Form 10-K, an inquiry was conducted by the Company's audit committee into the Company's understatement of its United States (U.S.) federal income tax payments and its provision for income taxes. The audit committee completed its inquiry in January 2008. On August 1, 2007, the audit committee, on the recommendation of management, concluded that the Company's previously issued financial statements for each of the eight fiscal years in the period ended July 31, 2006 (including the interim periods within those years), and for each of the fiscal quarters ended October 31, 2006, January 31, 2007 and April 30, 2007, should no longer be relied upon. Accordingly, the Company has restated its previously issued financial statements for those periods in its 2007 Form 10-K. The Company has not amended its previously filed Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q for the periods affected by this restatement. The financial information presented below for fiscal year 2007 has been restated as set forth in the 2007 Form 10-K.

This matter resulted in the Company's failure or inability to comply with certain representations, warranties and covenants in its debt and other financing-related agreements, including the Company's obligation to provide certain information (principally the Company's periodic Securities and Exchange Commission (SEC) reports) to those lenders or counterparties. The Company entered into amendments and/or waivers to address these matters with the lenders or counterparties, as applicable, under its \$500,000 unsecured senior revolving credit facility, Yen 9 billion variable-rate loan due June 20, 2010 and certain other debt and financing-related agreements, as well as an amendment of the indenture relating to the \$280,000 6% senior notes due August 1, 2012. Under the terms of those amendments and covenant waivers, the Company was obligated to return to compliance with its reporting obligations under the federal securities laws by March 31, 2008. As of the date hereof, the Company is in compliance with its filing obligations under the foregoing agreements, as amended.

The following tables present the effects of the adjustments made to the Company's previously reported statements of earnings for the three and six months ended January 31, 2007 for the restatement of the Company's provision for income taxes and interest expense, net.



Edgar Filing: PALL CORP - Form 10-Q

|                             |           |             |           |
|-----------------------------|-----------|-------------|-----------|
| Provision for income taxes  | 20,742    | 10,068      | 30,810    |
| Net earnings                | \$ 80,237 | \$ (19,889) | \$ 60,348 |
| Earnings per share:         |           |             |           |
| Basic                       | \$ 0.65   |             | \$ 0.49   |
| Diluted                     | \$ 0.64   |             | \$ 0.49   |
| Average shares outstanding: |           |             |           |
| Basic                       | 122,988   |             | 122,988   |
| Diluted                     | 124,392   |             | 124,392   |

7

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(In thousands, except per share data)**  
**(Unaudited)**

**NOTE 3 ADOPTION OF NEW ACCOUNTING PRONOUNCEMENTS**

In June 2006, the Financial Accounting Standards Board ( FASB ) issued Financial Interpretation No. 48, Accounting for Uncertainty in Income Taxes ( FIN No. 48 ). FIN No. 48 establishes a recognition threshold and measurement process for recording income tax positions in an enterprise s financial statements in accordance with SFAS No. 109, Accounting for Income Taxes. FIN No. 48 prescribes a two-step evaluation process for income tax positions. The first step is recognition and, if the recognition threshold is met, a second step, measurement, is applied. For recognition, an enterprise judgmentally determines whether it is more-likely-than-not that an income tax position will be sustained upon examination, including resolution of related appeals or litigation processes, based on the technical merits of the position. If the income tax position meets the more-likely-than-not recognition threshold it is measured and the appropriate amount is recognized in the financial statements as the largest amount of income tax benefit that is greater than 50% likely of being realized. If an income tax position does not meet the more-likely-than-not recognition threshold, no benefit for that position is recognized in the financial statements. Income tax positions that meet the more-likely-than-not recognition threshold at the effective date of FIN No. 48 may be recognized or, continue to be recognized, upon adoption of FIN No. 48.

Effective August 1, 2007, the Company adopted FIN No. 48 and in accordance with FIN No. 48, the Company recognized a cumulative-effect adjustment of \$5,600, reducing its liability for unrecognized income tax benefits and interest and increasing the August 1, 2007 balance of Retained Earnings.

At August 1, 2007, the Company had \$210,000 in gross tax reserves for unrecognized income tax benefits. The Company s uncertain income tax positions, if recognized, would reduce income tax expense by approximately \$135,000 thus favorably affecting the Company s effective tax rate.

In addition, consistent with the provisions of FIN No. 48, the Company reclassified \$210,000 of income tax liabilities from current to non-current liabilities because payment of cash is not anticipated within one year of the balance sheet date. These non-current income tax liabilities are recorded in Income taxes payable non-current in the condensed consolidated balance sheet.

The Company and its subsidiaries are currently subject to examination by various taxing authorities. While it is possible that one or more of these examinations may be resolved within the next twelve months, the Company does not anticipate a significant impact to the unrecognized income tax benefits.

The Company recognizes accrued interest expense related to unrecognized income tax benefits in interest expense and the balance at the end of a reporting period is recorded in accrued interest payable on the Company s condensed consolidated balance sheet. Penalties are accrued as part of income tax expense and the unpaid balance at the end of a reporting period are recorded as part of the current or non-current reserve for uncertain income tax positions. At August 1, 2007, the Company had accrued \$64,000 for the potential payment of interest and penalties. At January 31, 2008, the accrued balance for the potential payment of interest and penalties was \$70,000.

As of August 1, 2007, the Company is subject to U.S. federal and state and local income tax examinations for the fiscal tax years ended in 1996 through 2007, and to non-U.S. income tax examinations for the fiscal tax years ended in 2000 through 2007.

The balance of the Company s gross uncertain income tax positions at the end of the second quarter is \$220,000.

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

**NOTE 4 BALANCE SHEET DETAILS**

The following tables provide details of selected balance sheet items:

|  | <b>Jan. 31,<br/>2008</b> | <b>July 31,<br/>2007</b> |
|--|--------------------------|--------------------------|
| Accounts receivable:                   |                          |                          |
| Billed                                 | \$ 523,967               | \$ 510,991               |
| Unbilled                               | 65,135                   | 52,212                   |
| Total                                  | 589,102                  | 563,203                  |
| Less: Allowances for doubtful accounts | (12,898)                 | (11,810)                 |
|  | \$ 576,204               | \$ 551,393               |

Unbilled receivables principally relate to long-term contracts recorded under the percentage-of-completion method of accounting.

|   | <b>Jan. 31,<br/>2008</b> | <b>July 31,<br/>2007</b> |
|---|--------------------------|--------------------------|
| Inventories:                                    |                          |                          |
| Raw materials and components                    | \$ 149,342               | \$ 136,248               |
| Work-in-process                                 | 84,298                   | 73,725                   |
| Finished goods                                  | 272,725                  | 261,494                  |
|   | \$ 506,365               | \$ 471,467               |
|   | <b>Jan. 31, 2008</b>     | <b>July 31, 2007</b>     |
| Property, plant and equipment:                  |                          |                          |
| Property, plant and equipment                   | \$ 1,434,992             | \$ 1,370,287             |
| Less: Accumulated depreciation and amortization | (806,921)                | (762,387)                |
|   | \$ 628,071               | \$ 607,900               |

**NOTE 5 GOODWILL AND INTANGIBLE ASSETS**

The following table presents goodwill, net of accumulated amortization recorded prior to adopting SFAS No. 142, Goodwill and Other Intangible Assets ( SFAS No. 142 ), allocated by reportable segment, in accordance with SFAS No. 142.

|               | <b>Jan. 31,<br/>2008</b> | <b>July 31,<br/>2007</b> |
|---------------|--------------------------|--------------------------|
| Life Sciences | \$ 71,375                | \$ 69,433                |
| Industrial    | 192,278                  | 190,772                  |
|               | \$ 263,653               | \$ 260,205               |

The change in the carrying amount of goodwill is primarily attributable to changes in foreign exchange rates used to translate the goodwill contained in the financial statements of foreign subsidiaries using the rates at each respective balance sheet date.

Intangible assets, net, consist of the following:

|                                   |                  | <b>Jan. 31, 2008</b> |                  |
|-----------------------------------|------------------|----------------------|------------------|
|                                   | <b>Gross</b>     | <b>Accumulated</b>   | <b>Net</b>       |
|                                   |                  | <b>Amortization</b>  |                  |
| Patents and unpatented technology | \$ 84,358        | \$ 40,767            | \$ 43,591        |
| Trademarks                        | 4,855            | 2,887                | 1,968            |
| Other                             | 5,061            | 1,870                | 3,191            |
|                                   | <b>\$ 94,274</b> | <b>\$ 45,524</b>     | <b>\$ 48,750</b> |

Table of Contents

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

|                                   | <b>Gross</b>     | <b>July 31, 2007<br/>Accumulated<br/>Amortization</b> | <b>Net</b>       |
|-----------------------------------|------------------|---|------------------|
| Patents and unpatented technology | \$ 82,561        | \$ 37,369   | \$ 45,192        |
| Trademarks                        | 4,818            | 2,671   | 2,147            |
| Other                             | 2,275            | 1,681   | 594              |
|                                   | <b>\$ 89,654</b> | <b>\$ 41,721</b>                                      | <b>\$ 47,933</b> |

Amortization expense for intangible assets for the three and six months ended January 31, 2008 was \$1,988 and \$4,093, respectively. Amortization expense for intangible assets for the three and six months ended January 31, 2007 was \$2,041 and \$4,063, respectively. Amortization expense is estimated to be approximately \$3,614 for the remainder of fiscal year 2008, \$7,046 in fiscal year 2009, \$6,804 in fiscal year 2010, \$6,591 in fiscal year 2011, \$6,348 in fiscal year 2012 and \$3,640 in fiscal year 2013.

**NOTE 6 TREASURY STOCK**

On October 14, 2004, the Company's board of directors authorized the expenditure of up to \$200,000 for the repurchase of shares of the Company's common stock. On November 15, 2006, the board of directors authorized an additional expenditure of \$250,000 to repurchase shares. The Company's shares may be purchased over time, as market and business conditions warrant. There is no time restriction on this authorization. During the six months ended January 31, 2008, the Company did not purchase shares in open-market transactions. At January 31, 2008, approximately \$348,232 remained available to be expended under the current stock repurchase programs. Repurchased shares are held in treasury for use in connection with the Company's stock-based compensation plans and for general corporate purposes.

During the six months ended January 31, 2008, 326 shares were issued under the Company's stock-based compensation plans. At January 31, 2008, the Company held 5,086 treasury shares.

**NOTE 7 CONTINGENCIES AND COMMITMENTS**

With respect to the matters described below under the headings Federal Securities Class Actions, Shareholder Derivative Lawsuits and Other Proceedings, no liabilities or insurance recoveries have been reflected in the condensed consolidated financial statements as of January 31, 2008 as these amounts are not currently estimable.

**Federal Securities Class Actions:**

Four putative class action lawsuits have been filed against the Company and certain members of its management team alleging violations of the federal securities laws relating to the Company's understatement of certain of its U.S. income tax payments and of its provision for income taxes in certain prior periods described in Note 2, Audit Committee Inquiry and Restatement. These lawsuits were filed between August 14, 2007 and October 11, 2007 in the United States District Court for the Eastern District of New York. The plaintiffs principally allege that the defendants violated the federal securities laws by issuing materially false and misleading public statements about the Company's financial results, financial statements, income tax liability, effective tax rate and internal controls. The plaintiffs seek unspecified compensatory damages, costs and expenses. On October 15, 2007, various plaintiffs and groups of plaintiffs filed motions seeking to consolidate the cases and to be appointed lead plaintiff. These motions have not been decided.

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(In thousands, except per share data)**  
**(Unaudited)**

**Shareholder Derivative Lawsuits:**

On October 5, 2007, two plaintiffs filed identical derivative lawsuits in New York Supreme Court, Nassau County relating to the tax matter described above. These actions purport to bring claims on behalf of the Company based on allegations that certain current and former directors and officers of the Company breached their fiduciary duties by failing to evaluate and otherwise inform themselves about the Company's internal controls and financial reporting systems and procedures. In addition, plaintiffs allege that certain officers of the Company were unjustly enriched as a result of the Company's inaccurate financial results over fiscal years 1999-2006. The complaints seek unspecified compensatory damages on behalf of Pall Corporation, disgorgement of defendants' salaries, bonuses, stock grants and stock options, equitable relief and costs and expenses. The Company, acting in its capacity as nominal defendant, moved to dismiss the complaints on December 17, 2007 for failure to make a demand upon the Company's board of directors prior to filing the lawsuits, which motion is pending.

Another shareholder derivative lawsuit relating to the tax matter described above was filed in the United States District Court for the Eastern District of New York on January 10, 2008. This action purports to bring claims on behalf of the Company based on allegations that certain of the current directors of the Company breached their fiduciary duties and were unjustly enriched in connection with the tax matter. The complaint seeks unspecified compensatory damages on behalf of Pall Corporation, disgorgement of defendants' profits, benefits and other compensation, equitable and non-monetary relief, and costs and expenses. The Company, acting in its capacity as nominal defendant, moved to dismiss the complaint on March 10, 2008, for lack of subject matter jurisdiction over the complaint, which motion is pending.

**Other Proceedings:**

The SEC and U.S. Attorney's Office for the Eastern District of New York are conducting investigations in connection with the tax matter described above. The Company is cooperating with these investigations.

**Environmental Matters:**

The Company's condensed consolidated balance sheet at January 31, 2008 includes liabilities for environmental matters of approximately \$16,670, which relates primarily to the previously reported environmental proceedings involving a Company subsidiary, Gelman Sciences Inc., pertaining to groundwater contamination. In the opinion of management, the Company is in substantial compliance with applicable environmental laws and its current accruals for environmental remediation are adequate. However, as regulatory standards under environmental laws are becoming increasingly stringent, there can be no assurance that future developments, additional information and experience gained will not cause the Company to incur material environmental liabilities or costs beyond those accrued in its condensed consolidated financial statements.



**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

**NOTE 8 RESTRUCTURING AND OTHER CHARGES/(GAINS), NET**

The following tables summarize the restructuring and other charges/(gains) ( ROTC ) recorded for the three and six months ended January 31, 2008 and January 31, 2007:

|   | <b>Three Months Ended Jan. 31, 2008</b> |                               |              | <b>Six Months Ended Jan. 31, 2008</b> |                               |              |
|---|---|-------------------------------|--------------|---------------------------------------|-------------------------------|--------------|
|   | <b>Restructuring</b>                    | <b>Other</b>                  | <b>Total</b> | <b>Restructuring</b>                  | <b>Other</b>                  | <b>Total</b> |
|   |   | <b>Charges</b>                |              |                                       | <b>Charges</b>                |              |
|   | <b>(1)</b>                              | <b>/(Gains)</b><br><b>(2)</b> |              | <b>(1)</b>                            | <b>/(Gains)</b><br><b>(2)</b> |              |
| Severance                                 | \$ 2,801                                | \$                            | \$ 2,801     | \$ 7,657                              | \$                            | \$ 7,657     |
| Costs related to inquiry (2a)             |   | 9,900                         | 9,900        |                                       | 13,666                        | 13,666       |
| Other exit costs                          | 1,119                                   |                               | 1,119        | 1,624                                 |                               | 1,624        |
| (Gain)/loss on disposal of assets         | (188)                                   |                               | (188)        | (158)                                 | (484)                         | (642)        |
| Environmental matters (2b)                |   | 317                           | 317          |                                       | 600                           | 600          |
| Other                                     |   |                               |              |                                       | 13                            | 13           |
|   | 3,732                                   | 10,217                        | 13,949       | 9,123                                 | 13,795                        | 22,918       |
| Reversal of excess restructuring reserves | (90)                                    |                               | (90)         | (290)                                 |                               | (290)        |
|   | \$ 3,642                                | \$ 10,217                     | \$ 13,859    | \$ 8,833                              | \$ 13,795                     | \$ 22,628    |
| Cash                                      | \$ 3,642                                | \$ 10,217                     | \$ 13,859    | \$ 8,803                              | \$ 13,795                     | \$ 22,598    |
| Non-cash                                  |   |                               |              | 30                                    |                               | 30           |
|   | \$ 3,642                                | \$ 10,217                     | \$ 13,859    | \$ 8,833                              | \$ 13,795                     | \$ 22,628    |

|  | <b>Three Months Ended Jan. 31, 2007</b> |                               |              | <b>Six Months Ended Jan. 31, 2007</b> |                               |              |
|--|---|-------------------------------|--------------|---------------------------------------|-------------------------------|--------------|
|  | <b>Restructuring</b>                    | <b>Other</b>                  | <b>Total</b> | <b>Restructuring</b>                  | <b>Other</b>                  | <b>Total</b> |
|  |   | <b>Charges</b>                |              |                                       | <b>Charges</b>                |              |
|  | <b>(1)</b>                              | <b>/(Gains)</b><br><b>(2)</b> |              | <b>(1)</b>                            | <b>/(Gains)</b><br><b>(2)</b> |              |
| Severance                                  | \$ 6,914                                | \$                            | \$ 6,914     | \$ 14,725                             | \$                            | \$ 14,725    |
| Gain on sale and impairment of assets, net | (10,886)                                |                               | (10,886)     | (5,114)                               |                               | (5,114)      |
| Other exit costs                           | 167                                     |                               | 167          | 821                                   |                               | 821          |
| Environmental matters (2b)                 |   | 217                           | 217          |                                       | 2,561                         | 2,561        |
| Other                                      | 1,117                                   | (188)                         | 929          | 1,117                                 | 975                           | 2,092        |
|  | (2,688)                                 | 29                            | (2,659)      | 11,549                                | 3,536                         | 15,085       |

Edgar Filing: PALL CORP - Form 10-Q

|                             |            |       |            |          |          |           |
|-----------------------------|------------|-------|------------|----------|----------|-----------|
| Reversal of excess reserves | (989)      |       | (989)      | (1,645)  |          | (1,645)   |
|                             | \$ (3,677) | \$ 29 | \$ (3,648) | \$ 9,904 | \$ 3,536 | \$ 13,440 |
| Cash                        | \$ (1,154) | \$ 29 | \$ (1,125) | \$ 6,655 | \$ 3,536 | \$ 10,191 |
| Non-cash                    | (2,523)    |       | (2,523)    | 3,249    |          | 3,249     |
|                             | \$ (3,677) | \$ 29 | \$ (3,648) | \$ 9,904 | \$ 3,536 | \$ 13,440 |

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

## (1) Restructuring:

Following the completion of the integration of the Filtration and Separations Group ( FSG ), which was acquired in fiscal year 2002, Company management began a much broader initiative to examine the overall structure of the Company and the manner in which it conducted business activities with the objective of increasing revenue growth and achieving cost reduction. This resulted in a series of restructuring activities, including the realignment of the overall business structure into vertically integrated businesses, which commenced at the end of fiscal year 2004, the Company's facilities rationalization initiative and European cost reduction ( EuroPall ) initiative, which commenced in fiscal year 2006, and the Western Hemisphere cost reduction ( AmeriPall ) initiative, which commenced in fiscal year 2007.

## Three and Six Months Ended January 31, 2007:

The Company continued its cost reduction initiatives, including its facilities rationalization and EuroPall initiatives. As a result, the Company recorded severance liabilities for the termination of certain employees worldwide as well as other costs related to these initiatives.

In the three months ended January 31, 2007, the Company sold its corporate headquarters and recorded a gain on the sale of \$10,886.

In the three months ended October 31, 2006, the Company recorded an impairment charge of \$5,772 related to the planned disposal of a building in Europe and the early retirement of certain long-lived assets, as part of the Company's facilities rationalization initiative.

## Three and Six Months Ended January 31, 2008:

The Company continued its cost reduction initiatives, including its facilities rationalization, EuroPall and AmeriPall initiatives. As a result, the Company recorded severance liabilities for the termination of certain employees worldwide as well as other costs related to these initiatives.

The following table summarizes the activity related to restructuring liabilities that were recorded in the six months ended January 31, 2008 and in fiscal years 2007, 2006 and 2005:

|                          | <b>Severance</b> | <b>Lease<br/>Termination<br/>Liabilities<br/>&amp;<br/>Other</b> | <b>Total</b> |
|--------------------------|------------------|--|--------------|
| <b><u>2008</u></b>       |                  |  |              |
| Original charge          | \$ 7,657         | \$ 1,624   | \$ 9,281     |
| Utilized                 | (5,658)          | (1,342)  | (7,000)      |
| Other changes (a)        | 111              |  | 111          |
| Balance at Jan. 31, 2008 | \$ 2,110         | \$ 282   | \$ 2,392     |
| <b><u>2007</u></b>       |                  |  |              |
| Original charge          | \$ 22,083        | \$ 4,321   | \$ 26,404    |
| Utilized                 | (6,146)          | (3,573)  | (9,719)      |
| Other changes (a)        | 611              | 9  | 620          |

Edgar Filing: PALL CORP - Form 10-Q

|                                 |          |        |           |
|---------------------------------|----------|--------|-----------|
| Balance at Jul. 31, 2007        | 16,548   | 757    | 17,305    |
| Utilized                        | (7,788)  | (376)  | (8,164)   |
| Reversal of excess reserves (b) | (49)     | (59)   | (108)     |
| Other changes (a)               | 944      | 41     | 985       |
| Balance at Jan. 31, 2008        | \$ 9,655 | \$ 363 | \$ 10,018 |

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

|                                 | Severance | Lease<br>Termination<br>Liabilities<br>&<br>Other | Total     |
|---------------------------------|-----------|---|-----------|
| <b>2006</b>                     |           |   |           |
| Original charge                 | \$ 13,335 | \$ 3,043  | \$ 16,378 |
| Utilized                        | (7,221)   | (2,900)   | (10,121)  |
| Other changes (a)               | 182       | 9   | 191       |
| Balance at July 31, 2006        | 6,296     | 152   | 6,448     |
| Utilized                        | (2,712)   | (108)   | (2,820)   |
| Reversal of excess reserves (b) | (1,385)   | (40)  | (1,425)   |
| Other changes (a)               | 126       | 2   | 128       |
| Balance at Jul. 31, 2007        | 2,325     | 6   | 2,331     |
| Utilized                        | (1,104)   | (1)   | (1,105)   |
| Reversal of excess reserves (b) | (18)      |   | (18)      |
| Other changes (a)               | (4)       |   | (4)       |
| Balance at Jan. 31, 2008        | \$ 1,199  | \$ 5  | \$ 1,204  |
| <b>2005</b>                     |           |   |           |
| Original charge                 | \$ 17,496 | \$ 2,928  | \$ 20,424 |
| Utilized                        | (8,404)   | (2,739)   | (11,143)  |
| Other changes (a)               | (86)      | 4   | (82)      |
| Balance at July 31, 2005        | 9,006     | 193   | 9,199     |
| Utilized                        | (3,243)   | (87)  | (3,330)   |
| Reversal of excess reserves (b) | (1,905)   | (96)  | (2,001)   |
| Other changes (a)               | 57        | 3   | 60        |
| Balance at July 31, 2006        | 3,915     | 13  | 3,928     |
| Utilized                        | (2,531)   |   | (2,531)   |
| Reversal of excess reserves (b) | (811)     | (15)  | (826)     |
| Other changes (a)               | 31        | 2   | 33        |
| Balance at Jul. 31, 2007        | 604       |   | 604       |
| Utilized                        | (442)     |   | (442)     |
| Reversal of excess reserves (b) | (164)     |   | (164)     |
| Other changes (a)               | 2         |   | 2         |
| Balance at Jan. 31, 2008        | \$        | \$  | \$        |

(a) Other changes primarily reflect translation impact.

(b) Reflects the reversal of excess restructuring reserves originally recorded in fiscal years 2005, 2006 and 2007.

(2) Other Charges/(Gains):

(a) Costs related to inquiry:

In the three months and six months ended January 31, 2008, the Company recorded costs of \$9,900 and \$13,666, respectively, primarily comprised of legal and other professional fees related to the audit committee's inquiry into the Company's understatement of its U.S. federal income tax payments and its provision for income taxes. See Note 2, Audit Committee Inquiry and Restatement, for a description of this inquiry.

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

## (b) Environmental matters:

In the three and six months ended January 31, 2007, the Company recorded additional charges of \$217 and \$2,561, respectively, to increase its previously established environmental reserves primarily related to environmental matters in Ann Arbor, Michigan and Pinellas Park, Florida.

In the three month and six months ended January 31, 2008, the Company increased its previously established environmental reserves by \$317 and \$600, respectively, related to environmental matters in Ann Arbor, Michigan and Pinellas Park, Florida.

**NOTE 9 -INCOME TAXES**

The Company's effective tax rate for the six months ended January 31, 2008 and January 31, 2007 was 33.5% and 33.8% (as restated), respectively. During the six months ended January 31, 2008, a discrete tax charge was recorded resulting from tax legislation enacted in Germany. The Company is required to revalue its deferred tax assets and liabilities to reflect newly enacted rates which were reduced by the new tax law from approximately 38% to approximately 28% resulting in a reduction of net deferred tax assets. The German tax rate change as well as other discrete net charges related to enacted law changes increased the tax rate for the six month period ended January 31, 2008 by approximately 1.7%. This increase was partially offset by reductions in the tax impact of intercompany transactions.

In September 2007, the Company deposited \$135,000 with the Internal Revenue Service. A portion of this deposit has been reflected as a reduction of current income taxes payable and the remainder is reflected as an other non-current asset in the condensed consolidated balance sheet.

**NOTE 10 COMPONENTS OF NET PERIODIC PENSION COST**

The Company provides substantially all domestic and foreign employees with retirement benefits. Net periodic pension benefit cost for the Company's defined benefit pension plans includes the following components:

|  | U.S. Plans          |                  | Three Months Ended<br>Foreign Plans |                  | Total               |                  |
|--|---------------------|------------------|-------------------------------------|------------------|---------------------|------------------|
|  | Jan.<br>31,<br>2008 | Jan. 31,<br>2007 | Jan.<br>31,<br>2008                 | Jan. 31,<br>2007 | Jan.<br>31,<br>2008 | Jan. 31,<br>2007 |
| Service cost                             | \$ 2,000            | \$ 1,952         | \$ 1,045                            | \$ 905           | \$ 3,045            | \$ 2,857         |
| Interest cost                            | 2,893               | 2,760            | 4,809                               | 4,079            | 7,702               | 6,839            |
| Expected return on plan assets           | (2,190)             | (2,124)          | (4,011)                             | (3,250)          | (6,201)             | (5,374)          |
| Amortization of prior service cost       | 276                 | 275              | 84                                  | 153              | 360                 | 428              |
| Amortization of net transition asset     |                     | (11)             |                                     |                  |                     | (11)             |
| Recognized actuarial loss                | 467                 | 579              | 1,110                               | 2,152            | 1,577               | 2,731            |
| Loss due to curtailments and settlements |                     |                  | 4                                   |                  | 4                   |                  |
| Net periodic benefit cost                | \$ 3,446            | \$ 3,431         | \$ 3,041                            | \$ 4,039         | \$ 6,487            | \$ 7,470         |

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

|  | U.S. Plans          |                  | Six Months Ended<br>Foreign Plans |                  | Total            |                  |
|--|---------------------|------------------|-----------------------------------|------------------|------------------|------------------|
|  | Jan.<br>31,<br>2008 | Jan. 31,<br>2007 | Jan.<br>31,<br>2008               | Jan. 31,<br>2007 | Jan. 31,<br>2008 | Jan. 31,<br>2007 |
| Service cost                             | \$ 4,000            | \$ 3,904         | \$ 1,961                          | \$ 1,802         | \$ 5,961         | \$ 5,706         |
| Interest cost                            | 5,786               | 5,520            | 9,513                             | 8,027            | 15,299           | 13,547           |
| Expected return on plan assets           | (4,380)             | (4,248)          | (7,968)                           | (6,389)          | (12,348)         | (10,637)         |
| Amortization of prior service cost       | 552                 | 550              | 164                               | 304              | 716              | 854              |
| Amortization of net transition asset     |                     | (22)             |                                   |                  |                  | (22)             |
| Recognized actuarial loss                | 934                 | 1,158            | 2,200                             | 4,230            | 3,134            | 5,388            |
| Loss due to curtailments and settlements |                     |                  | 7                                 |                  | 7                |                  |
| Net periodic benefit cost                | \$ 6,892            | \$ 6,862         | \$ 5,877                          | \$ 7,974         | \$ 12,769        | \$ 14,836        |

**NOTE 11 STOCK-BASED PAYMENT**

The Company applies the provisions of SFAS No. 123(R), Share-Based Payment, which establishes the accounting for employee stock-based awards. The Company currently has four stock-based employee and directors compensation plans (Stock Option Plans, Management Stock Purchase Plan ( MSPP ), Employee Stock Purchase Plan ( ESPP ) and Restricted Stock Unit Plans), which are more fully described in Note 17, Common Stock, to the consolidated financial statements included in the 2007 Form 10-K.

The detailed components of stock-based compensation expense recorded in the condensed consolidated statements of earnings for the three and six months ended January 31, 2008 and January 31, 2007 are reflected in the table below.

|                        | Three Months Ended  |                  | Six Months Ended    |                  |
|------------------------|---------------------|------------------|---------------------|------------------|
|                        | Jan.<br>31,<br>2008 | Jan. 31,<br>2007 | Jan.<br>31,<br>2008 | Jan. 31,<br>2007 |
| Stock options          | \$ 846              | \$ 935           | \$ 1,474            | \$ 2,408         |
| Restricted stock units | 2,155               | 1,809            | 3,626               | 2,824            |
| ESPP                   | 1,056               | 143              | 1,875               | 760              |
| MSPP                   | 598                 | 891              | 1,118               | 1,302            |
| Total                  | \$ 4,655            | \$ 3,778         | \$ 8,093            | \$ 7,294         |

The following table illustrates the income tax effects related to stock-based compensation.

|  | Three Months Ended |                  | Six Months Ended |                  |
|--|--------------------|------------------|------------------|------------------|
|  | Jan. 31,<br>2008   | Jan. 31,<br>2007 | Jan. 31,<br>2008 | Jan. 31,<br>2007 |



Edgar Filing: PALL CORP - Form 10-Q

|  |        |         |        |         |
|--|--------|---------|--------|---------|
| Excess tax benefit in cash flows from financing activities   | \$ 206 | \$2,323 | \$ 760 | \$2,919 |
| Tax benefit recognized related to total stock-based compensation expense                                 | 1,368  | 869     | 2,261  | 1,418   |
| Actual tax benefit realized for tax deductions from option exercises of stock-based payment arrangements | 630    | 3,587   | 1,927  | 4,375   |
|  | 16     |         |        |         |

---

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

A summary of option activity for all stock option plans during the six months ended January 31, 2008 is presented below:

| Options                              | Shares | Weighted-Average<br>Exercise<br>Price | Weighted-Average<br>Remaining<br>Contractual<br>Term<br>(in years) | Aggregate<br>Intrinsic<br>Value |
|--------------------------------------|--------|---------------------------------------|--|---------------------------------|
| Outstanding at August 1, 2007        | 2,829  | \$ 25.29                              |  |                                 |
| Granted                              | 4      | 38.20                                 |  |                                 |
| Exercised                            | (21)   | 19.91                                 |  |                                 |
| Forfeited or Expired                 | (1)    | 28.15                                 |  |                                 |
| Outstanding at October 31, 2007      | 2,811  | \$ 25.35                              | 4.9  | \$ 42,615                       |
| Granted                              | 30     | 39.07                                 |  |                                 |
| Exercised                            | (1)    | 18.67                                 |  |                                 |
| Forfeited or Expired                 | (22)   | 30.07                                 |  |                                 |
| Outstanding at January 31, 2008      | 2,818  | \$ 25.46                              | 4.6  | \$ 33,714                       |
| Expected to vest at January 31, 2008 | 796    | \$ 33.49                              | 5.5  | \$ 4,245                        |
| Exercisable at January 31, 2008      | 1,998  | \$ 22.12                              | 4.3  | \$ 29,346                       |

As of January 31, 2008, there was \$5,764 of total unrecognized compensation cost related to nonvested stock options, which is expected to be recognized over a weighted-average period of 2.6 years. The total intrinsic value of options exercised during the three and six months ended January 31, 2008 was \$19 and \$412, respectively. The total intrinsic value of options exercised during the three and six months ended January 31, 2007 was \$8,939 and \$11,171, respectively.

The ESPP enables participants to purchase shares of the Company's common stock through payroll deductions at a price equal to 85% of the lower of the market price at the beginning or end of each semi-annual stock purchase period. The semi-annual offering periods end in April and October. A total of 200 shares and 233 shares were issued under the ESPP during the semi-annual stock purchase periods ended October 31, 2007 and October 31, 2006, respectively. Shares for the current semi-annual stock purchase period will be purchased on April 30, 2008.

The following weighted average assumptions were used in estimating the fair value of stock options and ESPP shares granted during the three and six months ended January 31, 2008 and January 31, 2007:

|   | Three Months Ended  |                  | Six Months Ended    |                  |
|---|---------------------|------------------|---------------------|------------------|
|   | Jan.<br>31,<br>2008 | Jan. 31,<br>2007 | Jan.<br>31,<br>2008 | Jan. 31,<br>2007 |
| <b>Stock Options</b>                      |                     |                  |                     |                  |
| Weighted average fair value at grant date | \$ 9.13             | \$ 8.86          | \$ 9.20             | \$ 8.84          |
| Valuation assumptions:                    |                     |                  |                     |                  |

Edgar Filing: PALL CORP - Form 10-Q

|                         |       |       |       |       |
|-------------------------|-------|-------|-------|-------|
| Expected dividend yield | 1.7%  | 1.9%  | 1.7%  | 1.9%  |
| Expected volatility     | 25.5% | 26.0% | 25.5% | 26.0% |
| Expected life (years)   | 5.0   | 5.0   | 5.0   | 5.0   |
| Risk-free interest rate | 3.2%  | 4.7%  | 3.3%  | 4.7%  |

**ESPP**

|   |                    |                    |                    |                    |
|---|--------------------|--------------------|--------------------|--------------------|
| Weighted average fair value at grant date | \$ 10.13           | \$ 6.89            | \$ 10.13           | \$ 6.89            |
| Valuation assumptions:                    |                    |                    |                    |                    |
| Expected dividend yield                   | 1.2%               | 1.6%               | 1.2%               | 1.6%               |
| Expected volatility                       | 37.1%              | 22.0%              | 37.1%              | 22.0%              |
| Expected life (years)                     | $\frac{1}{2}$ year | $\frac{1}{2}$ year | $\frac{1}{2}$ year | $\frac{1}{2}$ year |
| Risk-free interest rate                   | 4.0%               | 5.1%               | 4.0%               | 5.1%               |

17

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

The fair value of the options and ESPP shares granted is estimated using a Black-Scholes-Merton option-pricing formula and amortized to expense over the options' service periods. The Company has placed exclusive reliance on historical volatility in its estimate of expected volatility. The Company used a sequential period of historical data equal to the expected term (or expected life) of the options and ESPP shares granted using a simple average calculation based upon the daily closing prices of the aforementioned period.

The expected life (years) represents the period of time for which the options and ESPP shares granted are expected to be outstanding. This estimate was derived from historical share option exercise experience, which management believes provides the best estimate of the expected term.

The purpose of the MSPP is to encourage key employees of the Company to increase their ownership of shares of the Company's common stock by providing such employees with an opportunity to elect to have portions of their total annual compensation paid in the form of restricted units, to make cash purchases of restricted units and to earn additional matching restricted units which vest over a three year period for matches prior to August 1, 2003 and vest over a four year period for matches made thereafter. Such restricted units aggregated 804 and 819 as of January 31, 2008 and January 31, 2007, respectively. As of January 31, 2008, there was \$6,230 of total unrecognized compensation cost related to nonvested restricted stock units granted under the MSPP, which is expected to be recognized over a weighted-average period of 3.0 years.

The following is a summary of MSPP activity during the three and six months ended January 31, 2008 and January 31, 2007:

|  | <b>Three Months Ended</b> |                          | <b>Six Months Ended</b>  |                          |
|--|---------------------------|--------------------------|--------------------------|--------------------------|
|  | <b>Jan. 31,<br/>2008</b>  | <b>Jan. 31,<br/>2007</b> | <b>Jan. 31,<br/>2008</b> | <b>Jan. 31,<br/>2007</b> |
| Deferred compensation and cash contributions | \$ 445                    | \$ 1,112                 | \$ 3,089                 | \$ 2,967                 |
| Fair value of restricted stock units vested  | \$ 271                    | \$ 147                   | \$ 1,022                 | \$ 155                   |
| Vested units distributed                     | 50                        | 73                       | 140                      | 74                       |

A summary of restricted stock unit activity, related to employees, for the 2005 Stock Plan during the six months ended January 31, 2008, is presented below:

|                               | <b>Shares</b> | <b>Weighted-Average<br/>Grant-Date<br/>Fair Value</b> |
|-------------------------------|---------------|---|
| Nonvested at August 1, 2007   | 718           | \$ 33.19  |
| Granted                       | 18            | 38.20   |
| Vested                        | (1)           | 28.34   |
| Forfeited                     | (2)           | 34.55   |
| Nonvested at October 31, 2007 | 733           | 33.31   |
| Granted                       | 1             | 36.55   |
| Vested                        | (2)           | 30.02   |
| Forfeited                     | (17)          | 33.96   |
| Nonvested at January 31, 2008 | 715           | 33.31   |

As of January 31, 2008, there was \$14,710 of total unrecognized compensation cost related to nonvested restricted stock units granted under the 2005 Stock Plan, which is expected to be recognized over a weighted-average period of 2.9 years.

Non-employee directors of the Company were granted 18 annual award units of restricted stock during the three and six months ended January 31, 2008, with a weighted-average fair market value of \$39.00 per share.

The Company uses treasury shares that have been repurchased through the Company's stock repurchase program to satisfy share award exercises.

Table of Contents

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

## NOTE 12 EARNINGS PER SHARE

The condensed consolidated statements of earnings present basic and diluted earnings per share. Basic earnings per share is determined by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share considers the potential effect of dilution on basic earnings per share assuming potentially dilutive shares that meet certain criteria, such as those issuable upon exercise of stock options, were outstanding. The treasury stock method reduces the dilutive effect of potentially dilutive securities as it assumes that cash proceeds (from the issuance of potentially dilutive securities) are used to buy back shares at the average share price during the period. Employee stock options and units aggregating 662 and 404 shares were not included in the computation of diluted shares for the three months ended January 31, 2008 and January 31, 2007, respectively, because their effect would have been antidilutive. For the six months ended January 31, 2008 and January 31, 2007, 673 and 389 antidilutive shares, respectively, were excluded. The following is a reconciliation between basic shares outstanding and diluted shares outstanding:

|                            | <b>Three Months Ended</b> |                          | <b>Six Months Ended</b>  |                          |
|----------------------------|---------------------------|--------------------------|--------------------------|--------------------------|
|                            | <b>Jan. 31,<br/>2008</b>  | <b>Jan. 31,<br/>2007</b> | <b>Jan. 31,<br/>2008</b> | <b>Jan. 31,<br/>2007</b> |
| Basic shares outstanding   | 123,372                   | 123,185                  | 123,256                  | 122,988                  |
| Effect of stock plans      | 1,200                     | 1,319                    | 1,193                    | 1,404                    |
| Diluted shares outstanding | 124,572                   | 124,504                  | 124,449                  | 124,392                  |

## NOTE 13 COMPREHENSIVE INCOME

|   | <b>Three Months Ended</b> |  | <b>Six Months Ended</b>  |  |
|---|---------------------------|--|--------------------------|--|
|   | <b>Jan. 31,<br/>2008</b>  | <b>Jan. 31,<br/>2007<br/>(As<br/>Restated)</b> | <b>Jan. 31,<br/>2008</b> | <b>Jan. 31,<br/>2007<br/>(As<br/>Restated)</b> |
| Net earnings (a)                                    | \$ 47,988                 | \$ 44,347                                      | \$ 84,090                | \$ 60,348                                      |
| Unrealized translation adjustment (a)               | (1,564)                   | 4,572  | 21,812                   | 7,244  |
| Income taxes  | 1,464                     |  | 3,903                    | 168  |
| Unrealized translation adjustment, net              | (100)                     | 4,572  | 25,715                   | 7,412  |
| Change in unrealized investment (losses) gains      | (361)                     | 309  | 1,680                    | 2,101  |
| Income taxes  | 130                       | (1,417)  | (590)                    | (1,417)  |
| Change in unrealized investment (losses) gains, net | (231)                     | (1,108)  | 1,090                    | 684  |
| Unrealized (losses) gains on derivatives            | (317)                     | (93)   | (870)                    | 10   |

Edgar Filing: PALL CORP - Form 10-Q

|   |           |           |            |           |
|---|-----------|-----------|------------|-----------|
| Income taxes                                  | 135       | 7         | 287        | 20        |
| Unrealized (losses) gains on derivatives, net | (182)     | (86)      | (583)      | 30        |
| Total comprehensive income                    | \$ 47,475 | \$ 47,725 | \$ 110,312 | \$ 68,474 |

(a) Net earnings and unrealized translation adjustment have been restated for the three and six months ended January 31, 2007 as more fully described in Note 2, Audit Committee Inquiry and Restatement.

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(In thousands, except per share data)  
(Unaudited)

Unrealized investment gains on available-for-sale securities, net of related taxes, consist of the following:

|   | <b>Three Months Ended</b>    |                          | <b>Six Months Ended</b>      |                          |
|---|------------------------------|--------------------------|------------------------------|--------------------------|
|   | <b>Jan.<br/>31,<br/>2008</b> | <b>Jan. 31,<br/>2007</b> | <b>Jan.<br/>31,<br/>2008</b> | <b>Jan. 31,<br/>2007</b> |
| Unrealized (losses) gains arising during the period             | \$ (361)                     | \$ 267                   | \$ 1,680                     | \$ 1,782                 |
| Income taxes  | 130                          | (1,417)                  | (590)                        | (1,417)                  |
| Net unrealized (losses) gains arising during the period         | (231)                        | (1,150)                  | 1,090                        | 365                      |
| Reclassification adjustment for losses included in net earnings |                              | 42                       |                              | 319                      |
| Change in unrealized investment (losses) gains, net             | \$ (231)                     | \$ (1,108)               | \$ 1,090                     | \$ 684                   |

**NOTE 14 SEGMENT INFORMATION**

The Company's reportable segments as identified in accordance with the provisions of SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information, which are also its operating segments, consist of the Company's two vertically integrated businesses, Life Sciences and Industrial.

The following table presents sales and operating profit by segment reconciled to earnings before income taxes, for the three and six months ended January 31, 2008 and January 31, 2007.

|  | <b>Three Months Ended</b> |  | <b>Six Months Ended</b>  |  |
|--|---------------------------|--|--------------------------|--|
|  | <b>Jan. 31,<br/>2008</b>  | <b>Jan. 31,<br/>2007<br/>(As<br/>Restated)</b> | <b>Jan. 31,<br/>2008</b> | <b>Jan. 31, 2007<br/>(As<br/>Restated)</b> |
| <b>SALES:</b>  |                           |  |                          |  |
| Life Sciences  | \$ 244,480                | \$ 211,935                                     | \$ 459,094               | \$ 404,937                                 |
| Industrial   | 381,267                   | 332,995  | 727,660                  | 639,281                                    |
| Total  | \$ 625,747                | \$ 544,930                                     | \$ 1,186,754             | \$ 1,044,218                               |
| <b>OPERATING PROFIT:</b>   |                           |  |                          |  |
| Life Sciences  | \$ 48,153                 | \$ 37,036                                      | \$ 87,936                | \$ 66,224                                  |
| Industrial   | 55,443                    | 48,373   | 100,520                  | 81,662                                     |
| Total operating profit   | 103,596                   | 85,409   | 188,456                  | 147,886                                    |
| General corporate expenses                                       | 12,257                    | 10,330   | 23,683                   | 20,317                                     |
| Earnings before ROTC, interest expense, net and income taxes (a) | 91,339                    | 75,079   | 164,773                  | 127,569                                    |
| ROTC (a)   | 13,859                    | (1,559)  | 22,628                   | 15,956                                     |



|                                  |           |           |            |           |
|----------------------------------|-----------|-----------|------------|-----------|
| Interest expense, net (b)        | 8,063     | 9,759     | 15,784     | 20,455    |
| Earnings before income taxes (b) | \$ 69,417 | \$ 66,879 | \$ 126,361 | \$ 91,158 |

(a) Included in ROTC for the purposes of evaluation of segment profitability are other adjustments recorded in cost of sales. For the three and six months ended January 31, 2007, such adjustments include incremental depreciation and other adjustments of \$1,523 and \$1,950, respectively, recorded in conjunction with the Company's facilities rationalization initiative. Furthermore, such adjustments include a charge of \$566 for the quarter and six months ended January 31, 2007 related to a one-time purchase accounting adjustment to record, at market value, inventory

acquired from BioSeptra. This resulted in a \$2,431 increase in acquired inventories in accordance with SFAS No. 141, Business Combinations ( SFAS No. 141 ), and a charge to cost of sales in the periods when the sale of a portion of the underlying inventory occurred. The adjustment is excluded from operating profit as management considers it non-recurring in nature because, although the Company acquired the manufacturing operations of BioSeptra, this adjustment was required by SFAS No. 141 as an elimination of the manufacturing profit in inventory acquired from BioSeptra and subsequently sold.

**Table of Contents**

**PALL CORPORATION AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(In thousands, except per share data)**  
**(Unaudited)**

(b) Interest expense, net and earnings before income taxes have been restated for the quarter and six months ended January 31, 2007 as more fully described in Note 2, Audit Committee Inquiry and Restatement.

**NOTE 15 FINANCIAL INSTRUMENTS**

In June 2005, pursuant to the execution of a Yen 3.5 billion loan from a U.S. dollar functional Netherlands subsidiary of the Company ( PNBV ) to a Japanese subsidiary of the Company ( NPL ), PNBV entered into a cross currency swap with a financial institution. Under the terms of the agreement, PNBV will make interest payments to the financial institution at a fixed rate, based upon a notional amount of Yen 3.5 billion. In return, the financial institution will make interest payments to PNBV, at a fixed rate, based upon a \$32,154 notional amount (the U.S. dollar equivalent of the Yen 3.5 billion based upon the spot rate on the date of the closing of this transaction). At the end of this arrangement, PNBV will remit the Yen 3.5 billion principal, which it will receive from NPL, to the financial institution, who in turn will remit the \$32,154 to PNBV.

On December 12, 2007, the cross currency interest rate swap was settled and the intercompany loan was repaid. The cross currency swap had a gain of \$980 and the Japanese Yen intercompany loan had a foreign exchange loss of \$820. Both of these positions were recorded in the statement of earnings during the three months ended January 31, 2008.

**Table of Contents****ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.****Forward-Looking Statements and Risk Factors**

You should read the following discussion together with the accompanying condensed consolidated financial statements and notes thereto and other financial information in this Form 10-Q and in the 2007 Form 10-K. The discussions regarding sales under the subheading *Review of Operating Segments* below are in local currency unless otherwise indicated. Company management considers local currency growth an important measure because by excluding the volatility of exchange rates, underlying volume growth is clearer. Dollar amounts discussed below are in thousands, unless otherwise indicated, except per share dollar amounts. In addition, per share dollar amounts are discussed on a diluted basis.

The matters discussed in this Quarterly Report on Form 10-Q contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this and other written and oral reports are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. All statements regarding future performance, earnings projections, earnings guidance, management's expectations about its future cash needs and effective tax rate, and other future events or developments are forward-looking statements. Such risks and uncertainties include, but are not limited to: risks relating to the Company's restatement of prior period financial statements, including the risks associated with the pending Internal Revenue Service (IRS) audit and pending Securities and Exchange Commission (SEC) and Department of Justice investigations and litigation proceedings; risks associated with the Company's planned cash management initiatives, which may result in changes in the Company's effective tax rate; changes in product mix and product pricing may affect the Company's operating results particularly as the systems business expands in which significantly longer sales cycles are experienced with less predictable revenue and profitability and less certainty of future revenue streams from related consumable product offerings and services; increases in costs of manufacturing and operating costs, including energy and raw materials; the Company's ability to achieve the savings anticipated from its cost reduction and margin improvement initiatives including the timing of completion of its facilities rationalization initiative; fluctuations in foreign currency exchange rates and interest rates; regulatory approval or market acceptance of new technologies; changes in demand for the Company's products and business relationships with key customers and suppliers including delays or cancellations in shipments; success in enforcing patents and protecting proprietary products and manufacturing techniques; risks associated with the completion or integration of acquisitions; domestic and international competition; and global and regional economic conditions, including particularly the impact of current challenging conditions in the United States that may also have global implications; and legislative, regulatory and political developments. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them.

**Audit Committee Inquiry and Restatement**

As discussed in the 2007 Form 10-K, an inquiry was conducted by the Company's audit committee into the Company's understatement of its U.S. federal income tax payments and its provision for income taxes. The audit committee completed its inquiry in January 2008. On August 1, 2007, the audit committee, on the recommendation of management, concluded that the Company's previously issued financial statements for each of the eight fiscal years in the period ended July 31, 2006 (including the interim periods within those years), and for each of the fiscal quarters ended October 31, 2006, January 31, 2007 and April 30, 2007, should no longer be relied upon. Accordingly, the Company has restated its previously issued financial statements for those periods. The Company has not amended its previously filed Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q for the periods affected by this restatement. The financial information presented below for fiscal year 2007 has been restated as set forth in the 2007 Form 10-K.

**Results of Operations***Review of Consolidated Results*

Sales in the quarter increased 14.8% to \$625,747 from \$544,930 in the second quarter of fiscal year 2007. For the first six months, sales increased 13.7%, to \$1,186,754. Exchange rates increased reported sales by \$35,959 and \$63,821 in the quarter and six months, respectively, primarily due to the weakening of the U.S. dollar against the

Euro, the British Pound, the Yen and various other Asian currencies. In local currency (i.e., had exchange rates not changed year over year), sales increased 8.2% and 7.5% in the quarter and six months, respectively. Increased pricing driven by the Life Sciences segment contributed about 1% to overall sales growth in the quarter and six months.

**Table of Contents**

Life Sciences segment sales increased 9.3% and 7.7% (in local currency) in the quarter and six months, respectively, attributable to growth in the BioPharmaceuticals and Medical markets. Industrial segment sales increased 7.5% and 7.4% (in local currency) in the quarter and six months, respectively, driven by growth in the General Industrial and Aerospace and Transportation markets. Overall systems sales increased 40% and 34.2% in the quarter and six months, respectively, primarily attributable to strong sales in the BioPharmaceuticals and General Industrial markets. Company management expects overall sales in local currency to increase in the mid-single digit range for the full fiscal year 2008, with growth in Industrial slightly outpacing Life Sciences. For a detailed discussion of sales, refer to the section Review of Operating Segments below.

Gross margin, as a percentage of sales, decreased 100 basis points in the quarter to 46.1% from 47.1% in the second quarter of fiscal year 2007. The decrease in gross margins was principally driven by a shift in product mix, to a higher percentage of systems sales (12.5% compared to 9.7% in the second quarter of fiscal year 2007), which are typically at lower margins than consumables as well as mix change to lower margin consumables. In addition, gross margins, as a percentage of sales, on Pall Industrial systems were approximately 4% lower due to a large number of low margin system sales recognized in the quarter. Incremental costs in Europe related to the facilities rationalization initiative also reduced gross margin in the quarter. Such incremental costs include validation costs incurred as manufacturing transfers to another Pall facility. These negative impacts were partly offset by improved pricing that contributed approximately 30 basis points in margin, savings generated from the Company's facilities rationalization initiative and other manufacturing cost reduction and efficiency programs, the impact of improved profitability of systems sales, and product portfolio rationalization.

For the first six months, gross margin, as a percentage of sales, increased 30 basis points to 46.3% from 46.0% in the same period of fiscal year 2007. The improvement in gross margins was principally driven by improved pricing that contributed approximately 40 basis points in margin, savings generated from the Company's facilities rationalization initiative and other manufacturing cost reduction and efficiency programs. These factors were partly offset by the impact of a shift in product mix, to a higher percentage of systems sales (11.5% compared to 9.2% in the first six months of fiscal year 2007), mix change to lower margin consumables, decreased margins on certain Industrial systems sales and incremental costs in Europe related to the facilities rationalization initiative, as discussed above. Company management expects gross margin to be flat to slightly improved for the full fiscal year 2008 compared to fiscal year 2007.

Selling, general and administrative (SG&A) expenses in the quarter increased by \$10,642, or about 6% (approximately 1% in local currency). As a percentage of sales, SG&A expenses decreased to 28.6% from 30.9% in the second quarter of fiscal year 2007. SG&A expenses in the six months increased by \$24,254, or about 7% (approximately 2% in local currency). As a percentage of sales, SG&A expenses in the six months decreased to 29.5% from 31.2% in the same period of fiscal year 2007. The decrease in SG&A as a percentage of sales in the quarter and six months reflects the leveraging of growth in sales, and the impact of cost reduction initiatives, including the initiative to optimize the Company's European operations (EuroPall). In fiscal year 2007, the Company launched the equivalent of the EuroPall program in the Western Hemisphere (AmeriPall). This program is in the early implementation phase with the majority of the impact expected in fiscal year 2009 and beyond. For the full fiscal year 2008, Company management is expecting SG&A expenses, as a percentage of sales, to decrease approximately 100 basis points compared to fiscal year 2007.

Research and development expenses of \$18,092 increased about 18% from \$15,277 in the second quarter of fiscal year 2007. Research and development expenses in the six months of \$34,987 increased about 19% from \$29,511 in the same period of fiscal year 2007. As a percentage of sales, research and development expenses were 2.9% in the quarter and six months compared with 2.8% in the same periods of fiscal year 2007. Company management expects research and development expenses for the full fiscal year to increase approximately 15% compared to fiscal year 2007.

In the second quarter of fiscal year 2008, the Company recorded restructuring and other charges/(gains), net, (ROTC) of \$13,859. ROTC in the quarter was primarily comprised of legal and other professional fees related to matters under inquiry by the audit committee, as more fully described in Note 2, Audit Committee Inquiry and Restatement, to the accompanying condensed consolidated financial statements. Additionally, ROTC includes

severance liabilities and other exit costs related to the Company's on-going cost reduction initiatives (including its facilities rationalization, EuroPall and AmeriPall initiatives) as well as an increase to a previously established environmental reserve. Such charges were partly offset by the reversal of excess restructuring reserves previously recorded in the consolidated statements of earnings in fiscal years 2005, 2006 and 2007. In the first six months of fiscal year 2008, the Company recorded ROTC of \$22,628. ROTC in the six months was primarily comprised of legal and other professional fees related to matters under inquiry by the audit committee, as discussed above.

**Table of Contents**

Additionally, ROTC in the six months includes severance liabilities and other exit costs related to the Company's on-going cost reduction initiatives as well as an increase to a previously established environmental reserve. Such charges were partly offset by the reversal of excess restructuring reserves previously recorded in the consolidated statements of earnings in fiscal years 2005, 2006 and 2007.

In the second quarter of fiscal year 2007, the Company recorded a net gain of \$3,648 in ROTC primarily related to the Company's on-going cost reduction initiatives (including its facilities rationalization and EuroPall initiatives). ROTC in the quarter was primarily comprised of a gain on the sale of the Company's corporate headquarters and the reversal of excess restructuring reserves recorded in the consolidated statements of earnings in fiscal years 2005 and 2006, partly offset by severance costs. In the first six months of fiscal year 2007, the Company recorded ROTC of \$13,440 primarily related to the Company's on-going cost reduction initiatives. The charges in the six months were primarily comprised of severance liabilities and an impairment charge recorded in the first quarter related to the planned disposal of a building and early retirement of certain long-lived assets. Additionally, the charges in the six months include an increase to previously established environmental reserves. Such charges were partly offset by the gain on the sale of the Company's corporate headquarters and the reversal of excess restructuring reserves recorded in the consolidated statements of earnings in fiscal years 2005 and 2006.

The details of ROTC for the three and six months ended January 31, 2008 and January 31, 2007 can be found in Note 8, Restructuring and Other Charges/(Gains), Net, to the accompanying condensed consolidated financial statements.

The following table summarizes the activity related to restructuring liabilities that were recorded in the six months ended January 31, 2008 and in fiscal years 2007, 2006 and 2005:

|                                 | <b>Severance</b> | <b>Lease<br/>Termination<br/>Liabilities<br/>&amp;<br/>Other</b> | <b>Total</b> |
|---------------------------------|------------------|--|--------------|
| <b><u>2008</u></b>              |                  |  |              |
| Original charge                 | \$ 7,657         | \$ 1,624   | \$ 9,281     |
| Utilized                        | (5,658)          | (1,342)  | (7,000)      |
| Other changes (a)               | 111              |  | 111          |
| Balance at Jan. 31, 2008        | \$ 2,110         | \$ 282   | \$ 2,392     |
| <b><u>2007</u></b>              |                  |  |              |
| Original charge                 | \$ 22,083        | \$ 4,321   | \$ 26,404    |
| Utilized                        | (6,146)          | (3,573)  | (9,719)      |
| Other changes (a)               | 611              | 9  | 620          |
| Balance at Jul. 31, 2007        | 16,548           | 757  | 17,305       |
| Utilized                        | (7,788)          | (376)  | (8,164)      |
| Reversal of excess reserves (b) | (49)             | (59)   | (108)        |
| Other changes (a)               | 944              | 41   | 985          |
| Balance at Jan. 31, 2008        | \$ 9,655         | \$ 363   | \$ 10,018    |
| <b><u>2006</u></b>              |                  |  |              |
| Original charge                 | \$ 13,335        | \$ 3,043   | \$ 16,378    |



Edgar Filing: PALL CORP - Form 10-Q

|                                 |          |         |          |
|---------------------------------|----------|---------|----------|
| Utilized                        | (7,221)  | (2,900) | (10,121) |
| Other changes (a)               | 182      | 9       | 191      |
| Balance at July 31, 2006        | 6,296    | 152     | 6,448    |
| Utilized                        | (2,712)  | (108)   | (2,820)  |
| Reversal of excess reserves (b) | (1,385)  | (40)    | (1,425)  |
| Other changes (a)               | 126      | 2       | 128      |
| Balance at Jul. 31, 2007        | 2,325    | 6       | 2,331    |
| Utilized                        | (1,104)  | (1)     | (1,105)  |
| Reversal of excess reserves (b) | (18)     |         | (18)     |
| Other changes (a)               | (4)      |         | (4)      |
| Balance at Jan. 31, 2008        | \$ 1,199 | \$ 5    | \$ 1,204 |

**Table of Contents**

|                                 | <b>Severance</b> | <b>Lease<br/>Termination<br/>Liabilities<br/>&amp;<br/>Other</b> | <b>Total</b> |
|---------------------------------|------------------|--|--------------|
| <b>2005</b>                     |                  |  |              |
| Original charge                 | \$ 17,496        | \$ 2,928   | \$ 20,424    |
| Utilized                        | (8,404)          | (2,739)  | (11,143)     |
| Other changes (a)               | (86)             | 4  | (82)         |
| Balance at July 31, 2005        | 9,006            | 193  | 9,199        |
| Utilized                        | (3,243)          | (87)   | (3,330)      |
| Reversal of excess reserves (b) | (1,905)          | (96)   | (2,001)      |
| Other changes (a)               | 57               | 3  | 60           |
| Balance at July 31, 2006        | 3,915            | 13   | 3,928        |
| Utilized                        | (2,531)          |  | (2,531)      |
| Reversal of excess reserves (b) | (811)            | (15)   | (826)        |
| Other changes (a)               | 31               | 2  | 33           |
| Balance at Jul. 31, 2007        | 604              |  | 604          |
| Utilized                        | (442)            |  | (442)        |
| Reversal of excess reserves (b) | (164)            |  | (164)        |
| Other changes (a)               | 2                |  | 2            |
| Balance at Jan. 31, 2008        | \$               | \$   | \$           |

(a) Other changes primarily reflect translation impact.

(b) Reflects the reversal of excess restructuring reserves originally recorded in fiscal years 2005, 2006 and 2007.

Earnings before interest and income taxes ( EBIT ) were \$77,480 in the quarter compared to \$76,638 in the second quarter of fiscal year 2007. As a percentage of sales, EBIT was 12.4% in the quarter compared to 14.1% in the same period of fiscal year 2007. The increase in EBIT dollars reflects the impact of sales growth, including increased pricing and an improvement in SG&A as a percentage of sales. These factors were largely offset by a decrease in gross margin, as a percentage of sales, and an increase in ROTC that was primarily related to the Company's cost

reduction initiatives and matters under audit committee inquiry. EBIT for the first six months were \$142,145 compared to \$111,613 in the same period of fiscal year 2007. As a percentage of sales, EBIT was 12.0% in the first six months compared to 10.7% in the same period of fiscal year 2007. The increase in EBIT dollars reflects the impact of sales growth, including increased pricing and an improvement in gross margin and SG&A as a percentage of sales. These factors were partly offset by an increase in ROTC that was primarily related to the Company's cost reduction initiatives and audit committee inquiry.

Net interest expense in the quarter decreased to \$8,063 from \$9,759 (as restated) in the first quarter of fiscal year 2007. The decline in net interest expense was principally attributable to a decrease in the amount of interest expense recorded in the second quarter and first six months of fiscal year 2008 compared to the same periods in fiscal year 2007, related to the tax matter as discussed further in Note 2, Audit Committee Inquiry and Restatement, to the accompanying condensed consolidated financial statements. Company management expects net interest expense in fiscal year 2008 to increase compared to fiscal year 2007.

In the second quarter of fiscal year 2008, the Company's effective tax rate was 30.9% as compared to 33.7% (as restated) in the second quarter of fiscal year 2007. For the first six months of fiscal year 2008, the Company's effective tax rate was 33.5% as compared to 33.8% (as restated) in the same period of fiscal year 2007. See Note 9, Income Taxes, to the accompanying condensed consolidated financial statements for further details on the components of the Company's effective tax rate. The Company expects its effective tax rate to be approximately 33% for the full fiscal year 2008, inclusive of discrete items recognized in the six month period ended January 31, 2008. The actual effective tax rate may materially differ based on several factors including discrete items recognized in future periods. The Company's effective tax rate may change year to year based on recurring factors such as the geographical mix of earnings in tax jurisdictions that have a broad range of enacted tax rates, the timing and amount of foreign dividends, state and local taxes, the ratio of permanent items to pretax book income, and the implementation of various global tax strategies, as well as nonrecurring factors.

**Table of Contents**

Net earnings in the quarter were \$47,988, or 39 cents per share compared with net earnings of \$44,347, or 36 cents per share (as restated) in the second quarter of fiscal year 2007. In summary, net earnings reflect the growth in EBIT, a decrease in net interest expense and a decrease in the effective tax rate. Net earnings in the first six months were \$84,090, or 68 cents per share, compared with net earnings of \$60,348, or 49 cents per share (as restated) in the same period of fiscal year 2007. In summary, the increase in net earnings in the first six months reflects the increase in EBIT, a decrease in net interest expense and a decrease in the effective tax rate. Company management estimates that foreign currency translation increased net earnings by approximately 2 cents per share in the quarter and 4 cents per share in the six months.

*Review of Operating Segments*

Presented below is a summary of sales and operating profit by segment reconciled to earnings before income taxes, for the three and six months ended January 31, 2008 and January 31, 2007:

| <b><u>Three Months Ended</u></b>                                | <b>Jan. 31,<br/>2008</b> | <b>%<br/>Margin</b> | <b>Jan. 31,<br/>2007<br/>(As Restated)</b> | <b>%<br/>Margin</b> | <b>%<br/>Change</b> |
|---|--------------------------|---------------------|--|---------------------|---------------------|
| <b>SALES:</b>   |                          |                     |  |                     |                     |
| Life Sciences   | \$ 244,480               |                     | \$ 211,935                                 |                     | 15.4                |
| Industrial  | 381,267                  |                     | 332,995                                    |                     | 14.5                |
| Total   | \$ 625,747               |                     | \$ 544,930                                 |                     | 14.8                |
| <b>OPERATING PROFIT:</b>  |                          |                     |  |                     |                     |
| Life Sciences   | \$ 48,153                | 19.7                | \$ 37,036                                  | 17.5                | 30.0                |
| Industrial  | 55,443                   | 14.5                | 48,373                                     | 14.5                | 14.6                |
| Total operating profit  | 103,596                  | 16.6                | 85,409                                     | 15.7                | 21.2                |
| General corporate expenses                                      | 12,257                   |                     | 10,330                                     |                     | 18.7                |
| Earnings before ROTC, interest<br>expense, net and income taxes | 91,339                   | 14.6                | 75,079                                     | 13.8                | 21.7                |
| ROTC (a)  | 13,859                   |                     | (1,559)                                    |                     |                     |
| Interest expense, net (b)                                       | 8,063                    |                     | 9,759                                      |                     |                     |
| Earnings before income taxes (b)                                | \$ 69,417                |                     | \$ 66,879                                  |                     |                     |
| <br>  |                          |                     |  |                     |                     |
| <b><u>Six Months Ended</u></b>                                  | <b>Jan. 31,<br/>2008</b> | <b>%<br/>Margin</b> | <b>Jan. 31,<br/>2007<br/>(As Restated)</b> | <b>%<br/>Margin</b> | <b>%<br/>Change</b> |
| <b>SALES:</b>   |                          |                     |  |                     |                     |
| Life Sciences   | \$ 459,094               |                     | \$ 404,937                                 |                     | 13.4                |
| Industrial  | 727,660                  |                     | 639,281                                    |                     | 13.8                |
| Total   | \$ 1,186,754             |                     | \$ 1,044,218                               |                     | 13.7                |
| <b>OPERATING PROFIT:</b>  |                          |                     |  |                     |                     |
| Life Sciences   | \$ 87,936                | 19.2                | \$ 66,224                                  | 16.4                | 32.8                |
| Industrial  | 100,520                  | 13.8                | 81,662                                     | 12.8                | 23.1                |

Edgar Filing: PALL CORP - Form 10-Q

|  |            |      |           |      |      |
|--|------------|------|-----------|------|------|
| Total operating profit                                       | 188,456    | 15.9 | 147,886   | 14.2 | 27.4 |
| General corporate expenses                                   | 23,683     |      | 20,317    |      | 16.6 |
| Earnings before ROTC, interest expense, net and income taxes | 164,773    | 13.9 | 127,569   | 12.2 | 29.2 |
| ROTC (a)   | 22,628     |      | 15,956    |      |      |
| Interest expense, net (b)                                    | 15,784     |      | 20,455    |      |      |
| Earnings before income taxes (b)                             | \$ 126,361 |      | \$ 91,158 |      |      |

**Table of Contents**

(a) Included in ROTC for the purposes of evaluation of segment profitability are other adjustments recorded in cost of sales. For the three and six months ended January 31, 2007, such adjustments include incremental depreciation and other adjustments of \$1,523 and \$1,950, respectively, recorded in conjunction with the Company's facilities rationalization initiative. Furthermore, such adjustments include a charge of \$566 for the quarter and six months ended January 31, 2007 related to a one-time purchase accounting adjustment to record, at market value, inventory acquired from BioSeptra. This

resulted in a \$2,431 increase in acquired inventories in accordance with SFAS No. 141, Business Combinations, ( SFAS No. 141 ) and a charge to cost of sales in the periods when the sale of a portion of the underlying inventory occurred. The adjustment is excluded from operating profit as management considers it non-recurring in nature because, although the Company acquired the manufacturing operations of BioSeptra, this adjustment was required by SFAS No. 141 as an elimination of the manufacturing profit in inventory acquired from BioSeptra and subsequently sold.

- (b) Interest expense, net and Earnings before income taxes have been restated for the quarter and six

months ended  
January 31,  
2007, as more  
fully described  
in Note 2, Audit  
Committee  
Inquiry and  
Restatement, to  
the  
accompanying  
condensed  
consolidated  
financial  
statements.

**Life Sciences:**

Presented below are Summary Statements of Operating Profit for the Life Sciences segment for the three and six months ended January 31, 2008 and January 31, 2007:

| <u>Three Months Ended</u> | Jan. 31,<br>2008 | % of<br>Sales | Jan. 31,<br>2007 | % of<br>Sales |
|---------------------------|------------------|---------------|------------------|---------------|
| Sales                     | \$ 244,480       |               | \$ 211,935       |               |
| Cost of sales             | 123,137          | 50.4          | 105,921          | 50.0          |
| Gross margin              | 121,343          | 49.6          | 106,014          | 50.0          |
| SG&A                      | 62,982           | 25.8          | 61,136           | 28.8          |
| Research and development  | 10,208           | 4.2           | 7,842            | 3.7           |
| Operating profit          | \$ 48,153        | 19.7          | \$ 37,036        | 17.5          |
|                           |                  |               |                  |               |
| <u>Six Months Ended</u>   | Jan. 31,<br>2008 | % of<br>Sales | Jan. 31,<br>2007 | % of<br>Sales |
| Sales                     | \$ 459,094       |               | \$ 404,937       |               |
| Cost of sales             | 226,603          | 49.4          | 203,697          | 50.3          |
| Gross margin              | 232,491          | 50.6          | 201,240          | 49.7          |
| SG&A                      | 124,729          | 27.2          | 119,528          | 29.5          |
| Research and development  | 19,826           | 4.3           | 15,488           | 3.8           |
| Operating profit          | \$ 87,936        | 19.2          | \$ 66,224        | 16.4          |

The tables below present sales by market and geography within the Life Sciences segment for the three and six months ended January 31, 2008 and January 31, 2007, including the effect of exchange rates for comparative purposes.

| <u>Three Months Ended</u> | Jan. 31,<br>2008 | Jan. 31,<br>2007 | %<br>Change | Exchange<br>Rate<br>Impact | %<br>Change<br>in<br>Local<br>Currency |
|---------------------------|------------------|------------------|-------------|----------------------------|--|
|---------------------------|------------------|------------------|-------------|----------------------------|--|



Edgar Filing: PALL CORP - Form 10-Q

By Market

|                     |            |            |      |           |      |
|---------------------|------------|------------|------|-----------|------|
| Medical             | \$ 125,277 | \$ 119,605 | 4.7  | \$ 4,742  | 0.8  |
| BioPharmaceuticals  | 119,203    | 92,330     | 29.1 | 7,995     | 20.4 |
| Total Life Sciences | \$ 244,480 | \$ 211,935 | 15.4 | \$ 12,737 | 9.3  |

By Geography

|                     |            |            |      |           |      |
|---------------------|------------|------------|------|-----------|------|
| Western Hemisphere  | \$ 95,897  | \$ 89,441  | 7.2  | \$ 465    | 6.7  |
| Europe              | 117,471    | 95,249     | 23.3 | 10,162    | 12.7 |
| Asia                | 31,112     | 27,245     | 14.2 | 2,110     | 6.5  |
| Total Life Sciences | \$ 244,480 | \$ 211,935 | 15.4 | \$ 12,737 | 9.3  |

**Table of Contents**

| <u>Six Months Ended</u> | Jan. 31,<br>2008 | Jan. 31,<br>2007 | %<br>Change | Exchange<br>Rate<br>Impact | %<br>Change<br>in<br>Local<br>Currency |
|-------------------------|------------------|------------------|-------------|----------------------------|--|
| <u>By Market</u>        |                  |                  |             |                            |  |
| Medical                 | \$ 235,449       | \$ 223,117       | 5.5         | \$ 8,695                   | 1.6                                    |
| BioPharmaceuticals      | 223,645          | 181,820          | 23.0        | 14,175                     | 15.2                                   |
| Total Life Sciences     | \$ 459,094       | \$ 404,937       | 13.4        | \$ 22,870                  | 7.7                                    |
| <u>By Geography</u>     |                  |                  |             |                            |  |
| Western Hemisphere      | \$ 182,899       | \$ 173,637       | 5.3         | \$ 758                     | 4.9                                    |
| Europe                  | 218,493          | 179,921          | 21.4        | 18,626                     | 11.1                                   |
| Asia                    | 57,702           | 51,379           | 12.3        | 3,486                      | 5.5                                    |
| Total Life Sciences     | \$ 459,094       | \$ 404,937       | 13.4        | \$ 22,870                  | 7.7                                    |

Life Sciences segment sales increased 9.3% in the quarter compared to the second quarter of fiscal year 2007. Overall, increased pricing in the Medical and BioPharmaceuticals markets contributed about 1.5% to sales growth in the quarter, and as such, the overall volume increase was about 7.8%. For the first six months, Life Sciences segment sales increased 7.7% compared to the same period in fiscal year 2007. Overall, increased pricing, in the Medical and BioPharmaceuticals markets contributed about 1.6% to sales growth in the first six months and, as such, the overall volume increase was about 6.1%. Life Sciences represented about 39% of total sales in the quarter and six months on par with the same periods of fiscal year 2007. Company management expects overall Life Sciences sales to increase about 4% for the full fiscal year 2008 compared to fiscal year 2007.

Within Life Sciences, Medical sales, which represented approximately one-half of Life Sciences sales were flat driven by flat sales in Blood Filtration, the largest market served by Medical, as well as slightly down sales in the BioSciences market. A 10.3% increase in Hospital sales mitigated this impact. The growth in Hospital sales reflects increased Aquasafe sales in the Western Hemisphere, new tender awards in Europe and strong breathing filter sales in the Western Hemisphere and Asia. The decrease in the Blood Filtration market reflects decreases in Europe, related to lost or uncontested tenders and reduced blood draws primarily in the United Kingdom. Japan, which also has significantly reduced its blood draws, is also in transition from bedside filtration to blood centers. At this point, the decrease in the Company's sales to hospitals more than offsets increases in sales to blood centers. The Company is in the process of qualifying more of its blood filter models with blood centers. These negative impacts in Europe and Asia were partly offset by growth in the Western Hemisphere related to increased sales in Canada. Sales to Canada are expected to reduce for the second half of fiscal year 2008 with the expected expiration of a contract to one of the major blood centers. The decline in the BioSciences market was primarily driven by a decline in laboratory sales (in Europe and Asia) related to timing of shipments.

For the first six months, Medical sales increased 1.6% reflecting a slight increase in the Blood Filtration, the largest market served by Medical and growth of 8.1% in the Hospital market. Sales in the BioSciences market were down slightly (-0.4%). The growth in Hospital sales reflects the same trend evident in the quarter. The decrease in the Blood Filtration market reflects decreases in Europe and Asia as discussed above. These negative impacts were partly offset by growth in the Western Hemisphere related to increased sales in Canada, strong volume growth to U.S. independent blood centers as a result of expanding Acrodose and related in-line systems sales, increased sales in Latin America and the impact of an increase in pricing compared with the same period of fiscal year 2007. The decline in the

BioSciences market was primarily driven by a decline in laboratory sales (in Europe and the Western Hemisphere) related to timing of shipments. Company management expects overall Medical sales to be down slightly for the full fiscal year 2008 compared to fiscal year 2007.

**Table of Contents**

BioPharmaceuticals sales increased 20.4% driven by growth in systems sales of over 200% accompanied by growth in sales of consumables of 8.6%. By geography, growth in this market was led by Europe (+26.6%), which is the Company's largest geographic market in BioPharmaceuticals, accompanied by increases in the Western Hemisphere (+12.2%) and Asia (+12.6%). The growth in systems sales in the quarter reflects investment by the biotechnology sector in all geographies. The growth in consumables was attributable to double-digit sales growth in Europe as a result of Biotechnology manufacturing transfers from the United States and the impact of new plants coming on stream. A near double-digit decrease in consumables sales in the Western Hemisphere partly offset the above. This reduction was caused by sales downturns and inventory reduction programs in a number of large U.S. biotechnology customers. Consumables sales were up modestly in Asia (low single-digits), although, growth has been hampered by ongoing supply and contamination issues related to donated blood for plasma derivatives production in China. For the first six months, BioPharmaceuticals sales increased 15.2%, as systems sales more than doubled compared to the same period in fiscal year 2007, and consumables sales grew 7.4%. By geography, growth in this market was led by Europe (+22.3%), accompanied by increases in the Western Hemisphere (+5.1%) and Asia (+7.8%) as well. The growth in the six month period reflects the same trends evident in the quarter. Overall, key products driving growth are the Company's virus removal filters for biotechnology and plasma derived therapeutics, and its increasing portfolio of single-use processing technologies including the Kleenpak connector. Company management expects these broad trends to continue through the remainder of the year, with Europe strong and the Western Hemisphere weaker due to customer specific slowdowns, although beginning to improve later this year. Company management continued to see strong investment in the Western Hemisphere and Europe in systems and new manufacturing facilities and is continuing to see signs of large biotechnology manufacturing moving into Asia. These factors provides strong evidence that the medium term prospects for the Company's wider consumables business is also good as these new plants come on stream. For the full fiscal year 2008, Company management expects double-digit sales growth in the BioPharmaceuticals market compared to fiscal year 2007.

Life Sciences gross margins decreased 40 basis points to 49.6% from 50% in the second quarter of fiscal year 2007. The decrease in gross margins was principally driven by a shift in product mix, to a higher percentage of systems sales (7.3% compared to 2.6% in the second quarter of fiscal year 2007), which are typically at lower margins than consumables, partly offset by improved pricing that contributed approximately 70 basis points in margin and savings generated from cost reduction initiatives. For the first six months, Life Sciences gross margins increased 90 basis points to 50.6% from 49.7% in the same period of fiscal year 2007. The improvement in gross margins was principally driven by improved pricing that contributed approximately 70 basis points in margin and savings generated from cost reduction initiatives. These factors were partly offset by a shift in product mix, to a higher percentage of systems sales (6.4% compared to 3.1% in the same period of fiscal year 2007).

SG&A expenses increased by \$1,846, or 3% (a decrease of approximately 3% in local currency), compared to the second quarter of fiscal year 2007. For the first six months, SG&A expenses increased by \$5,201, or about 4% (a decrease of approximately 1% in local currency). SG&A expenses as a percentage of sales in the quarter decreased to 25.8% from 28.8% in the second quarter of fiscal year 2007. For the first six months, SG&A expenses as a percentage of sales decreased to 27.2% from 29.5%. The decrease in SG&A as a percentage of sales reflects the impact of the Company's cost reduction initiatives and the leveraging of growth in sales.

R&D expenses were up about 30% in the quarter (approximately 29% in local currency); coming in at \$10,208 compared to \$7,842 in the second quarter of fiscal year 2007. For the first six months, R&D expenses increased 28% (approximately 26% in local currency). As a percentage of sales, R&D expenses were 4.2% and 4.3% in the quarter and six months, respectively, compared to 3.7% and 3.8% in the same periods of fiscal year 2007. Increased spending reflects investments in prion, cell harvesting and blood projects.

As a result of the above factors, operating profit dollars in the quarter increased 30% to \$48,153 and operating margin improved to 19.7% from 17.5% in the second quarter of fiscal year 2007. For the first six months, operating profit dollars increased about 33% to \$87,936 and operating margin improved to 19.2% from 16.4% in the same period of fiscal year 2007.

**Table of Contents****Industrial:**

Presented below are Summary Statements of Operating Profit for the Industrial segment for the three and six months ended January 31, 2008 and January 31, 2007:

| <b><u>Three Months Ended</u></b> | <b>Jan. 31,<br/>2008</b> | <b>% of<br/>Sales</b> | <b>Jan. 31,<br/>2007</b> | <b>% of<br/>Sales</b> |
|----------------------------------|--------------------------|-----------------------|--------------------------|-----------------------|
| Sales                            | \$ 381,267               |                       | \$ 332,995               |                       |
| Cost of sales                    | 214,334                  | 56.2                  | 180,450                  | 54.2                  |
| Gross margin                     | 166,933                  | 43.8                  | 152,545                  | 45.8                  |
| SG&A                             | 103,606                  | 27.2                  | 96,737                   | 29.1                  |
| Research and development         | 7,884                    | 2.1                   | 7,435                    | 2.2                   |
| Operating profit                 | \$ 55,443                | 14.5                  | \$ 48,373                | 14.5                  |

| <b><u>Six Months Ended</u></b> | <b>Jan. 31,<br/>2008</b> | <b>% of<br/>Sales</b> | <b>Jan. 31,<br/>2007</b> | <b>% of<br/>Sales</b> |
|--------------------------------|--------------------------|-----------------------|--------------------------|-----------------------|
| Sales                          | \$ 727,660               |                       | \$ 639,281               |                       |
| Cost of sales                  | 410,559                  | 56.4                  | 357,863                  | 56.0                  |
| Gross margin                   | 317,101                  | 43.6                  | 281,418                  | 44.0                  |
| SG&A                           | 201,420                  | 27.7                  | 185,733                  | 29.1                  |
| Research and development       | 15,161                   | 2.1                   | 14,023                   | 2.2                   |
| Operating profit               | \$ 100,520               | 13.8                  | \$ 81,662                | 12.8                  |

The tables below present sales by market and geography within the Industrial segment for the three and six months ended January 31, 2008 and January 31, 2007, including the effect of exchange rates for comparative purposes.

|                                  | <b>Jan. 31,<br/>2008</b> | <b>Jan. 31,<br/>2007</b> | <b>%<br/>Change</b> | <b>Exchange<br/>Rate<br/>Impact</b> | <b>%<br/>Change<br/>in<br/>Local<br/>Currency</b> |
|----------------------------------|--------------------------|--------------------------|---------------------|-------------------------------------|---|
| <b><u>Three Months Ended</u></b> |                          |                          |                     |                                     |   |
| <b><u>By Market</u></b>          |                          |                          |                     |                                     |   |
| General Industrial               | \$ 232,005               | \$ 196,975               | 17.8                | \$ 16,583                           | 9.4   |
| Aerospace and Transportation     | 71,013                   | 60,735                   | 16.9                | 3,159                               | 11.7  |
| Microelectronics                 | 78,249                   | 75,285                   | 3.9                 | 3,480                               | (0.7)   |
| Total Industrial                 | \$ 381,267               | \$ 332,995               | 14.5                | \$ 23,222                           | 7.5   |
| <b><u>By Geography</u></b>       |                          |                          |                     |                                     |   |
| Western Hemisphere               | \$ 98,976                | \$ 96,949                | 2.1                 | \$ 964                              | 1.1   |
| Europe                           | 149,309                  | 131,687                  | 13.4                | 13,792                              | 2.9   |
| Asia                             | 132,982                  | 104,359                  | 27.4                | 8,466                               | 19.3  |

|                  |            |            |      |           |     |
|------------------|------------|------------|------|-----------|-----|
| Total Industrial | \$ 381,267 | \$ 332,995 | 14.5 | \$ 23,222 | 7.5 |
|------------------|------------|------------|------|-----------|-----|

**Table of Contents**

| <u>Six Months Ended</u>      | <b>Jan. 31,</b>   | <b>Jan. 31,</b>   | <b>%</b>      | <b>Exchange</b>  | <b>%</b>        |
|------------------------------|-------------------|-------------------|---------------|------------------|-----------------|
| <u>By Market</u>             | <b>2008</b>       | <b>2007</b>       | <b>Change</b> | <b>Rate</b>      | <b>Change</b>   |
|                              |                   |                   |               | <b>Impact</b>    | <b>in</b>       |
|                              |                   |                   |               |                  | <b>Local</b>    |
|                              |                   |                   |               |                  | <b>Currency</b> |
| General Industrial           | \$ 440,694        | \$ 372,048        | 18.5          | \$ 29,193        | 10.6            |
| Aerospace and Transportation | 137,272           | 121,067           | 13.4          | 6,196            | 8.3             |
| Microelectronics             | 149,694           | 146,166           | 2.4           | 5,562            | (1.4)           |
| <b>Total Industrial</b>      | <b>\$ 727,660</b> | <b>\$ 639,281</b> | <b>13.8</b>   | <b>\$ 40,951</b> | <b>7.4</b>      |
| <b>By Geography</b>          |                   |                   |               |                  |                 |
| Western Hemisphere           | \$ 195,909        | \$ 185,915        | 5.4           | \$ 1,746         | 4.4             |
| Europe                       | 281,768           | 251,120           | 12.2          | 25,682           | 2.0             |
| Asia                         | 249,983           | 202,246           | 23.6          | 13,523           | 16.9            |
| <b>Total Industrial</b>      | <b>\$ 727,660</b> | <b>\$ 639,281</b> | <b>13.8</b>   | <b>\$ 40,951</b> | <b>7.4</b>      |

Industrial segment sales grew 7.5% in the quarter and 7.4% in the first six months, driven by growth in the General Industrial and Aerospace and Transportation markets. Overall, pricing was flat in the quarter, however, for the first six months, improved pricing (achieved in the General Industrial market) contributed about 0.5% to the overall sales growth in the period. Industrial systems sales increased 20.4% and 21.2% in the quarter and first six months, respectively. The Company's Total Fluid Management<sup>®</sup> approach presents many opportunities for growth in this regard. While several markets contributed to the growth in systems sales, the Municipal Water market was the most significant growth driver. Industrial consumables sales grew 5.7% in the quarter and 5.3% in the first six months, primarily driven by the energy and industrial manufacturing markets. Industrial represented approximately 61% of total sales in the quarter and first six months, on par with the same periods in fiscal year 2007. Company management expects overall Industrial sales to increase about 6% for the full fiscal year 2008 compared to fiscal year 2007.

Within the Industrial segment, General Industrial market sales, which account for a little over 60% of the Industrial segment, were up 9.4% and 10.6% in the quarter and first six months, respectively, with all markets contributing to this gain.

Municipal Water sales, which comprise approximately 12% of General Industrial sales (and are primarily comprised of systems), increased 17.7% compared to the second quarter of fiscal year 2007, generated by growth in Asia, where sales increased over 300%. Sales in Europe were up modestly (+3.3%), while the Western Hemisphere was down about 10% due to lumpiness of projects. For the first six months, Municipal Water sales increased 42.5% compared to the same period in fiscal year 2007, generated by double-digit growth in all geographies. Growth in the Western Hemisphere for the first six months was primarily fueled by surface water treatment projects driven by government regulations. In Europe, key growth drivers in the quarter and six months include surface water treatment in the United Kingdom and various other countries, and sales of leachate systems in Eastern Europe. In Asia, the drought in Australia is a key growth driver and the sales growth in the quarter and first six months reflect a large wastewater recycle project in Australia. Overall, backlog in this market is up about 39%.

Sales in the energy-related marketplace increased 7.9% in the quarter reflecting growth in consumables in all geographies partly offset by a decline in systems sales. The decrease in systems sales reflects declines in Europe and the Western Hemisphere due to tough comparables to last year. Strong growth in Asia primarily related to a large water system project for an energy customer partly offset the above. For the first six months, sales in the

energy-related marketplace increased 6.1% reflecting growth in consumables in all geographies partly offset by a decline in systems sales. The decrease in systems sales reflects a decline in Europe due to tough comparables to last year, partly offset by strong growth in Asia. Market opportunities and growth drivers include alternative energy, including wind and coal gasification. Overall, backlog in this market is up about 6%. While modest sales growth is expected for the full fiscal year 2008 due to tough comparables versus fiscal year 2007, orders are expected to be strong in the second half of the year, particularly in the fuels and chemicals marketplace, boding well for fiscal year 2009.



**Table of Contents**

Food and Beverage sales were up 1.4% in the quarter reflecting double-digit growth in systems sales (contributed by Europe) partly offset by a slight decline in consumables (in Europe and Asia). For the first six months, Food and Beverage sales were up 2.9% reflecting mid-single digit growth in systems sales (contributed by Europe) and low single-digit growth in consumables (all geographies contributing). Sales in Europe, the Company's largest Food & Beverage market, were up in the high single digit range in both the quarter and first six months. Key growth drivers in Europe include sales of OenoFlow to the wine market, Aria systems for process water and expanding sales to the beer market. In the Western Hemisphere, sales increased in the quarter; however, they were down in the six months (mid single-digit range). In Asia, sales were down in both periods due to a delay in a large project to the second half of the year. Backlog in this market is up about 74% compared to the same period last year.

Sales in the Industrial Manufacturing market increased 17.3% in the quarter, generated by double-digit growth in Europe and Asia. Sales in the Western Hemisphere were down (mid single-digit range). For the first six months, sales in the Industrial Manufacturing market increased 15% generated by growth in all geographies. Demand in the mining and automotive sectors were key growth drivers in this market in the quarter and first six months.

Company management is expecting high-single digit growth in General Industrial for the full fiscal year 2008, with the largest growth expected in the Municipal Water and Industrial Manufacturing markets.

Aerospace and Transportation sales increased 11.7% driven by double-digit growth in the Military market supplemented by single-digit growth in both the Commercial and Transportation markets. The growth in Military sales was primarily driven by strong growth in Asia, where sales more than doubled related to a large systems project in Australia as well as increased consumables sales. The growth in Asia was accompanied by a double-digit increase in Military sales in the Western Hemisphere related to the CH-47 helicopter, while Europe was up modestly. The growth in the Commercial portion of this market primarily reflects strong after-market sales in the Western Hemisphere, while the increase in the Transportation market reflects growth in powertrain sales. For the first six months, Aerospace and Transportation sales increased 8.3% with all markets, Military, Commercial and Transportation contributing to this gain. The growth in Military sales (+6.9%) was primarily driven by strong growth in Asia, where sales more than doubled reflecting the factors discussed above. Military sales were down in the six months in the Western Hemisphere (-6.9%) and Europe (-8.2%). The growth in Commercial sales (+10.5%) reflects increased original equipment manufacturer sales (OEM) generated by an increase in airframe build rates, combined with strong after-market sales. The increase in the Transportation market (+7.4%) reflects growth in powertrain sales. Company management is expecting high-single digit growth in the Aerospace and Transportation market for the full fiscal year 2008.

Microelectronics sales decreased 0.7% as modest growth in Asia (+1%) was offset by decreases in the Western Hemisphere (-4.8%) and Europe (-3.1%). For the first six months, Microelectronics sales decreased 1.4% as growth in Asia (+2.9%) and Europe (+0.5%) was offset by a decrease in the Western Hemisphere (-15.6%). Overall, the sales decrease in the quarter and first six months reflects tough comparables against the strong growth achieved in the same periods last year and the current cyclical downturn in the market. These factors were partly mitigated by sales growth in the thin film rigid disc and inkjet markets in Asia. Based upon various market indicators, Company management is expecting low single-digit growth overall for the full fiscal year 2008.

Industrial gross margins in the quarter decreased 200 basis points to 43.8% from 45.8% in the second quarter of fiscal year 2007. The decrease in gross margins reflects the impact of a shift in product mix quarter over quarter, to a higher percentage of systems sales (15.9% compared to 14.2% in the second quarter of fiscal year 2007), which are typically at lower margins than consumables. Furthermore, gross margins, as a percentage of sales, on Pall Industrial systems were approximately 4% lower due to large number of low margin system sales recognized in the quarter. Gross margins were also negatively impacted by a shift in market mix, as Microelectronics market sales, whose products are typically sold at higher gross margins, declined as a percentage of total Industrial sales. In addition, gross margins reflect incremental costs in Europe related to the facilities rationalization initiative. These factors were partly offset by the impact of the Company's facilities rationalization initiative and other manufacturing cost reduction and efficiency programs, the impact of improved profitability of certain systems sales, and product portfolio rationalization. For the first six months, Industrial gross margins decreased 40 basis points to 43.6% from 44.0% in the same period of fiscal year 2007. The decrease in gross margins reflects the impact of a shift in product mix

(systems sales were 14.8% of total compared to 13.1% in the same period of fiscal year 2007), and market mix, the impact of a large number of low margin system sales recorded in the second quarter and incremental costs in Europe related to the facilities rationalization initiative, as discussed above, partially offset by the impact of improved profitability of certain systems sales, and product portfolio rationalization, the impact of the Company's manufacturing cost reduction programs and improved pricing that contributed almost 20 basis points in margin.

**Table of Contents**

SG&A expenses increased by \$6,869, or about 7% (approximately 1% in local currency), compared to the second quarter of fiscal year 2007. For the first six months, SG&A expenses increased by \$15,687, or about 8% (approximately 3% in local currency). SG&A expenses in the quarter improved to 27.2% as a percentage of sales from 29.1% in the second quarter of fiscal year 2007. For the first six months, SG&A expenses improved to 27.7% as a percentage of sales from 29.1% in the same period last year. The improvement in SG&A as a percentage of sales reflects the impact of cost reduction programs, particularly EuroPall and the leveraging of growth in sales.

R&D expenses were up 6% (approximately 3% in local currency), in the quarter; coming in at \$7,884 compared to \$7,435 in the second quarter of fiscal year 2007. For the first six months, R&D expenses increased approximately 8% (approximately 5% in local currency). As a percentage of sales, R&D expenses were 2.1% in the quarter and six months compared to 2.2% in the same periods of fiscal year 2007. Increased spending reflects investments in new technologies supporting specific initiatives principally in the Microelectronics market.

As a result of the above factors, operating profit dollars in the quarter increased about 15% to \$55,443 and operating margin was 14.5% on par with the second quarter of fiscal year 2007. For the first six months, operating profit dollars increased about 23% to \$100,520 and operating margin improved to 13.8% from 12.8% in the same period of fiscal year 2007.

**Corporate:**

Corporate expenses increased by \$1,927, or about 19% to \$12,257 from \$10,330 in the second quarter of fiscal year 2007. For the first six months of fiscal year 2008, Corporate expenses increased \$3,366, or about 17% to \$23,683 from \$20,317 in the same period of fiscal year 2007. The increase in Corporate expenses in the quarter and first six months primarily reflects the addition of tax and treasury function personnel and increased professional fees related to tax and audit services.

**Liquidity and Capital Resources**

Non-cash working capital, which is defined as working capital excluding cash and cash equivalents, notes receivable, notes payable and the current portion of long-term debt, was approximately \$694,500, a turnover ratio of 4.8 at January 31, 2008 as compared with \$372,400, a turnover ratio of 5.9 at July 31, 2007. Non-cash working capital at January 31, 2007 was \$369,900, a turnover ratio of 5.3. Accounts receivable days sales outstanding ( DSO ) was 83 days in the second quarter of fiscal year 2008 as compared to 78 days in the second quarter of fiscal year 2007. Inventory turns for the four quarters ended January 31, 2008 were 2.6 as compared to 2.7 for the four quarters ended January 31, 2007.

The Company's balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. dollars. In comparing spot exchange rates at January 31, 2008 to those at July 31, 2007, the Euro and the Yen have strengthened against the U.S. dollar, while the British Pound has weakened. The effect of foreign exchange increased non-cash working capital by \$24,835, including net inventory, net accounts receivable and other current assets by \$11,397, \$26,041 and \$3,398, respectively, as compared to July 31, 2007. Additionally, foreign exchange increased accounts payable and other current liabilities by \$14,975 and income tax payable by \$1,026.

Net cash used by operating activities in the first six months of fiscal year 2008 was \$74,905 as compared to net cash provided by operating activities of \$148,875 in the same period of fiscal year 2007, a decrease of \$223,780. The decrease in cash flow reflects a tax payment of \$135,000 to the IRS as well as changes in working capital items, particularly accounts receivable, accounts payable and accrued liabilities, partly offset by the impact of increased net earnings.

Free cash flow, which is defined as net cash provided by operating activities less capital expenditures, was \$(127,586) in the first six months of fiscal year 2008, as compared with \$116,665 in the first six months of fiscal year 2007. The decrease in free cash flow reflects the decrease in cash provided by operating activities as discussed and a higher level of capital expenditures. Company management believes this measure is important because it is a key element of its planning. The Company utilizes free cash flow, which is a non-GAAP measure, as one way to measure its current and future financial performance. The following table reconciles free cash flow to net cash provided by operating activities.

|   | <b>Six Months<br/>Ended<br/>Jan. 31, 2008</b> | <b>Six Months<br/>Ended<br/>Jan. 31, 2007</b> |
|---|---|---|
| Net cash provided by operating activities | \$ (74,905)                                   | \$ 148,875                                    |
| Less capital expenditures                 | 52,681  | 32,210  |
| Free cash flow                            | \$ (127,586)                                  | \$ 116,665                                    |

**Table of Contents**

Overall, net debt (debt net of cash and cash equivalents) as a percentage of total capitalization (net debt plus equity) was 23.2% at January 31, 2008 as compared to 15.2% at July 31, 2007. Net debt increased by approximately \$156,900 compared with July 31, 2007 primarily comprised of a decrease in cash and cash equivalents of \$47,800 and an increase in gross debt of \$110,800 reflecting the \$135,000 deposit with the IRS in September 2007. The impact of foreign exchange rates decreased net debt by about \$1,700.

As a result of the audit committee inquiry (refer to Note 2, Audit Committee Inquiry and Restatement, to the accompanying condensed consolidated financial statements), the Company failed to comply with certain representations, warranties and covenants in its debt agreements, including its inability to timely file its periodic reports with the SEC. The Company entered into amendments and/or waivers of those agreements. Under the terms of those amendments and waivers, the Company was obligated to return to compliance with its reporting obligations under the federal securities laws by March 31, 2008. As of the date hereof, the Company is in compliance with its covenants under the foregoing agreements, as amended by such instruments. Such matters did not affect the Company's compliance with the financial covenants, contained in its five-year revolving credit facility with a syndicate of financial institutions and its Yen 9 billion loan, which provide that the Company may not have a consolidated net interest coverage ratio based upon trailing four quarter results that is less than 3.50 to 1.00, nor a consolidated leverage ratio based upon trailing four quarter results that is greater than 3.50 to 1.00. The Company is in compliance with these financial covenants.

The Company utilizes cash flow generated from operations and its revolving credit facility to meet its short-term liquidity needs. Company management considers its existing lines of credit, along with the cash typically generated from operations, to be sufficient to meet its short-term liquidity needs.

Capital expenditures were \$52,681 in the first six months of fiscal year 2008 (\$29,095 expended in the current quarter). Capital expenditures reflect spending on the expansion of existing plants in Puerto Rico, the United States and Europe related to the facilities rationalization initiative. Depreciation expense was \$21,006 and \$41,699 in the quarter and six months, respectively. Amortization expense was \$2,072 and \$4,256 in the quarter and six months, respectively. For the full fiscal year 2008, capital expenditures are expected to be no more than \$130,000. Depreciation and amortization expense are expected to total approximately \$95,000.

On October 14, 2004, the Company's board of directors authorized the expenditure of up to \$200,000 for the repurchase of shares of the Company's common stock. On November 15, 2006, the board of directors authorized an additional expenditure of \$250,000 to repurchase shares. At July 31, 2007 there was \$348,232 available to be expended under these authorizations. The Company repurchased stock of \$11,800 in the first six months of fiscal year 2007 and \$61,795 for the full fiscal year ended July 31, 2007. In the first six months of fiscal year 2008, the Company did not repurchase stock and as such there was \$348,232 remaining at January 31, 2008 under the current stock repurchase programs. Net proceeds from stock plans were \$7,462 in the six months.

The Company increased its quarterly dividend by 9%, from 11 to 12 cents per share, effective with the dividend declared on January 11, 2007. In the first six months of fiscal year 2008, the Company paid dividends of \$29,425, an increase of approximately 9% compared to the first six months of fiscal year 2007. The Company increased its quarterly dividend from 12 to 13 cents per share, effective with the dividend declared on March 12, 2008.

**Recently Issued Accounting Pronouncements**

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements ( SFAS No. 157 ). SFAS No. 157 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. SFAS No. 157 is effective for the Company beginning with fiscal year 2009, except as revised by FASB Staff Position (FSP) No. 157-2, issued in February 2008. This FSP delays the effective date of SFAS No. 157 for non-financial assets and non-financial liabilities, except for items that are reorganized or disclosed at fair value in the financial statements on a periodic basis (at least annually). The Company is in the process of assessing the effect SFAS No. 157 may have on its consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities ( SFAS No. 159 ). SFAS No. 159 permits entities to elect to measure specified financial instruments and certain other items at fair value with changes in fair value recognized in earnings each reporting period. SFAS No. 159 is effective for the Company beginning with fiscal year 2009. The Company is in the process of assessing the effect

SFAS No. 159 may have on its consolidated financial statements.

**Table of Contents**

In June 2007, the FASB ratified Emerging Issues Task Force ( EITF ) No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities ( EITF No. 07-3 ). EITF No. 07-3 requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and capitalized and recognized as an expense as the related goods are delivered or the related services are performed. If an entity does not expect the goods to be delivered or services to be rendered, the capitalized advance payment should be charged to expense. EITF No. 07-3 is effective, on a prospective basis, for the Company beginning with fiscal year 2009. The Company is in the process of assessing the effect EITF No. 07-3 may have on its consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations ( SFAS No. 141(R) ). SFAS No. 141(R) establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree, recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase, and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS No. 141(R) is effective for the Company beginning with fiscal year 2010.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements an amendment of Accounting Research Bulletin No. 51 ( SFAS No. 160 ). SFAS No. 160 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parent s ownership interest, and the valuation of retained noncontrolling equity investments when a subsidiary is deconsolidated. SFAS No. 160 also establishes disclosure requirements that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS No. 160 is effective for the Company beginning with fiscal year 2010.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

There is no material change in the market risk information reported in Item 7A of the 2007 Form 10-K.

**ITEM 4. CONTROLS AND PROCEDURES.**

There was no change in the Company s internal control over financial reporting during the second quarter of fiscal year 2008 that has materially affected, or is reasonably likely to materially affect, the Company s internal control over financial reporting.

As reported in the 2007 Form 10-K, the Company s management identified a material weakness in its internal control over financial reporting related to its accounting for income taxes. Specifically, the Company lacked a periodic review to ensure that the income tax impact of certain intercompany transactions were properly considered in the Company s provision for income taxes. As a result of that material weakness, management concluded that the Company s disclosure controls and procedures were not effective as of July 31, 2007.

As discussed in its Form 10-Q for the quarter ended October 31, 2007, the Company implemented the additional controls and procedures listed below during the quarter ended October 31, 2007. As of the date of this report, the Company has implemented:

Changes in the resources and technical expertise of the Tax and Treasury functions, including the termination of the employment of four employees.

Additional processes requiring the monthly review of intercompany transactions to determine if balances are being settled in accordance with applicable intercompany settlement policies and to ensure that exceptions are given appropriate income tax consideration. In addition, a quarterly review of income in foreign subsidiaries that may be subject to U.S. income tax for inclusion in the Company s forecasted effective tax rate to be applied in its interim periods was implemented.

The Company is planning training initiatives for all employees affected by revisions to its policies and procedures, as well as specialized training with respect to tax considerations for relevant employees.

**Table of Contents**

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's chief executive officer and chief financial officer, of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based on this evaluation, the chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures are effective. The Company believes that the actions it has taken to date, including the implementation and testing of the additional controls and procedures outlined above, have remediated, as of January 31, 2008, its material weakness in internal control over financial reporting.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

**PART II. OTHER INFORMATION****ITEM 1. LEGAL PROCEEDINGS.****(In thousands)**

As previously disclosed in the 2007 Form 10-K, the Company is subject to various regulatory proceedings and litigation relating to various environmental matters and to the tax matters described in Note 2, Audit Committee Inquiry and Restatement, to the accompanying condensed consolidated financial statements. The information provided below updates and should be read in conjunction with the discussion of these proceedings in Part I Item 3 Legal Proceedings in the 2007 Form 10-K. Reference is also made to Note 7, Contingencies and Commitments, to the accompanying condensed consolidated financial statements.

**Federal Securities Class Actions:**

Four putative class action lawsuits have been filed against the Company and certain members of its management team alleging violations of the federal securities laws relating to the Company's understatement of certain of its U.S. income tax payments and of its provision for income taxes in certain prior periods described in Note 2, Audit Committee Inquiry and Restatement, to the accompanying condensed consolidated financial statements. These lawsuits were filed between August 14, 2007 and October 11, 2007 in the United States District Court for the Eastern District of New York. The plaintiffs principally allege that the defendants violated the federal securities laws by issuing materially false and misleading public statements about the Company's financial results, financial statements, income tax liability, effective tax rate and internal controls. The plaintiffs seek unspecified compensatory damages, costs and expenses. On October 15, 2007, various plaintiffs and groups of plaintiffs filed motions seeking to consolidate the cases and to be appointed lead plaintiff. These motions have not been decided.

**Shareholder Derivative Lawsuits:**

On October 5, 2007, two plaintiffs filed identical derivative lawsuits in New York Supreme Court, Nassau County relating to the tax matter described above. These actions purport to bring claims on behalf of the Company based on allegations that certain current and former directors and officers of the Company breached their fiduciary duties by failing to evaluate and otherwise inform themselves about the Company's internal controls and financial reporting systems and procedures. In addition, plaintiffs allege that certain officers of the Company were unjustly enriched as a result of the Company's inaccurate financial results over fiscal years 1999-2006. The complaints seek unspecified compensatory damages on behalf of Pall Corporation, disgorgement of defendants' salaries, bonuses, stock grants and stock options, equitable relief and costs and expenses. The Company, acting in its capacity as nominal defendant, moved to dismiss the complaints on December 17, 2007 for failure to make a demand upon the Company's board of directors prior to filing the lawsuits, which motion is pending.

Another shareholder derivative lawsuit relating to the tax matter described above was filed in the United States District Court for the Eastern District of New York on January 10, 2008. This action purports to bring claims on behalf of the Company based on allegations that certain of the current directors of the Company breached their fiduciary duties and were unjustly enriched in connection with the tax matter. The complaint seeks unspecified compensatory damages on behalf of Pall Corporation, disgorgement of defendants' profits, benefits and other



compensation, equitable and non-monetary relief, and costs and expenses. The Company, acting in its capacity as nominal defendant, moved to dismiss the complaint on March 10, 2008, for lack of subject matter jurisdiction over the complaint, which motion is pending.

**Table of Contents**

**Other Proceedings:**

The SEC and U.S. Attorney's Office for the Eastern District of New York are conducting investigations in connection with the tax matter described above. The Company is cooperating with these investigations.

**Environmental Matters**

The Company's condensed consolidated balance sheet at January 31, 2008 contains a reserve for environmental liabilities of approximately \$16,670, which relates primarily to the items discussed below. In the opinion of management, the Company is in substantial compliance with applicable environmental laws and its accruals for environmental remediation are adequate at this time.

**Pinellas Park, Florida:**

Pursuant to the Florida Department of Environmental Protection's (FDEP) request in January 2007, the Company installed additional monitoring wells, both on- and off-site. Upon completion of the monitoring activities, the Company will prepare a Site Assessment Report Addendum, delineating the soil and groundwater contamination for FDEP review. The report will also present the scope of all remediation tasks.

**Hauppauge, New York:**

While the motions related to the legal proceedings surrounding this matter were pending, the parties enlisted the aid of a mediator to negotiate a settlement of the case. The parties met with the mediator on July 30 through August 1, 2007, which resulted in a tentative settlement agreement, subject to drafting of definitive settlement documents. During the process of negotiating the settlement documents, a disagreement developed between the plaintiff and the primary defendants as to the terms of establishment of the settlement fund that had been agreed upon at the mediation. This dispute has not been resolved and the proposed settlement has not yet been achieved.

The summary judgment motions remains pending without a decision. On September 27, 2007, the Court issued a decision on Pall's motions *in limine* to preclude testimony by the experts for plaintiff and third-party plaintiff Barbara Gross, granting the motions in part and denying them in part.

If the settlement is completed as contemplated, Pall's responsibility will be fixed and it will be released from further liability to the plaintiff or third-party plaintiffs. If it is not completed and Pall's motion for summary judgment is denied the case will continue. If that happens, Pall will remain subject to potential liability and an allocation of some portion of the response costs paid by plaintiff to the State of New York.

**ITEM 1A. RISK FACTORS.**

There is no material change in the risk factors reported in Item 1A of the 2007 Form 10-K. This report contains certain forward-looking statements which reflect management's expectations regarding future events and operating performance and speak only as of the date hereof. These statements are subject to risks and uncertainties, which could cause actual results to differ materially. For a description of these risks see Management's Discussion and Analysis of Financial Condition and Results of Operations - Forward-Looking Statements and Risk Factors.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**

On December 4, 2007, the Company issued 100 shares and 870 shares of common stock upon the exercise of stock options granted under the 2005 Stock Compensation Plan and the 1998 Employee Stock Option Plan, respectively, by two employees. The stock options had exercise prices of \$25.85 and \$17.84, respectively. The Company intends to use the proceeds for general corporate purposes. These transactions were exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof.

**ITEM 6. EXHIBITS.**

See the Exhibit Index for a list of exhibits filed herewith or incorporated by reference herein.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Pall Corporation

March 28, 2008

/s/ LISA MCDERMOTT

Lisa McDermott

Chief Financial Officer and Treasurer

/s/ FRANCIS MOSCHELLA

Francis Moschella

Vice President - Corporate Controller

Chief Accounting Officer

38

---

**Table of Contents**

**EXHIBIT INDEX**

| Exhibit<br>Number | Description of Exhibit   |
|-------------------|--|
| 3(i)*             | Restated Certificate of Incorporation of the Registrant as amended through November 23, 1993, filed as Exhibit 3(i) to the Registrant's Annual Report on Form 10-K for the fiscal year ended July 30, 1994.  |
| 3(ii)*            | By-Laws of the Registrant as amended effective January 17, 2008, filed as Exhibit 3(ii) to the Registrant's Current Report on Form 8-K filed on January 18, 2008.  |
| 10*               | Second Amendment and Waiver, dated as of December 7, 2007 to the Five-Year Credit Agreement, dated as of June 21, 2006, among Pall Corporation, the subsidiaries of the Company named on the signature pages thereto, the lenders from time to time party thereto, JPMorgan Chase Bank, N.A., as facility agent for the Lenders, and J.P. Morgan Europe Limited, as London agent for the Lenders, filed as Exhibit 10 to the Registrant's Current Report on Form 8-K filed on December 11, 2007. |
| 31.1              | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| 31.2              | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| 32.1              | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.  |
| 32.2              | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.  |
| *                 | Incorporated herein by reference.  |
|                   | Exhibit filed herewith.  |